\-\ Texto\\:\\ \ \(0\)\
\-\ vs\\:\\ \\ bp\\ 130\\/80\\ mmhg\\,\\ hr\\ 78\\ bpm\\,\\ rr\\ 16\\ respirations\\ \\/\\ min\\,\\ \ \(0\)\
\-\ general\\:\\ 62\\"\\ african\\ american\\ female\\ weighing\\ 241\\ lbs\\.\\ \\(44\\.1\\ bmi\\)\\ in\\ no\\ acute\\ distress\\.\\ \ \(0\)\
\-\ skin\\:\\ moist\\,\\ regular\\ texture\\ and\\ color\\,\\ no\\ evidence\\ of\\ nodules\\ petechiae\\ edema\\ or\\ changes\\ in\\ pigmentation\\.\ \(0\)\
\-\ head\\:\\ normocephalic\\ and\\ atraumatic\\,\\ without\\ any\\ lesions\\ or\\ tenderness\\.\ \(0\)\
\-\ eyes\\:\\ prescription\\ glasses\\ noted\\.\\ bl\\ no\\ lid\\ lag\\ or\\ edema\\.\\ bl\\ conjunctiva\\ pink\\,\\ non\\-inflamed\\.\\ perrla\\.\\ sclera\\ white\\ and\\ anicteric\\.\\ eomi\\,\\ with\\ visual\\ fields\\ within\\ normal\\ limits\\.\ \(0\)\
\-\ ears\\:\\ no\\ external\\ lesions\\ or\\ deformities\\.\\ tm\\ pearly\\ grey\\,\\ and\\ regular\\ landmarks\\ visualized\\.\ \(0\)\
\-\ nose\\:\\ nares\\ patent\\.\\ sinuses\\ non\\-tender\\.\\ mucosal\\ membranes\\ pink\\ and\\ non\\-edematous\\.\ \(0\)\
\-\ mouth\\ \\/\\ throat\\:\\ regular\\ oral\\ mucosa\\,\\ non\\-erythematous\\ and\\ non\\-edematous\\.\\ no\\ lesions\\ or\\ ulcers\\.\\ normal\\ dentition\\.\ \(0\)\
\-\ neck\\:\\ normal\\ rom\\.\\ trachea\\ midline\\.\\ carotids\\ 2\\+\\.\\ thyroid\\ non\\-tender\\,\\ non\\-enlarged\\,\\ and\\ without\\ nodules\\.\\ no\\ lymph\\ node\\ prominence\\ appreciated\\.\\ \ \(0\)\
\-\ lungs\\:\\ equal\\ and\\ bl\\ breath\\ sounds\\.\\ normal\\ expansion\\.\\ no\\ rales\\,\\ rubs\\,\\ rhonchi\\,\\ or\\ wheeze\\ auscultated\\.\\ \ \(0\)\
\-\ heart\\:\\ pmi\\ regular\\.\\ regular\\ rate\\ and\\ rhythm\\.\\ s1\\ and\\ s2\\ appreciated\\.\\ no\\ murmurs\\,\\ gallops\\,\\ or\\ rubs\\.\\ peripheral\\ pulses\\ 2\\+\\.\ \(0\)\
\-\ abdomen\\:\\ regular\\ inspection\\.\\ bowel\\ sounds\\ heard\\ in\\ all\\ four\\ quadrants\\.\\ regular\\ liver\\ span\\.\\ non\\-tender\\.\\ \ \(0\)\
\-\ musculoskeletal\\:\\ regular\\ stability\\.\\ non\\-edematous\\ joints\\ with\\ normal\\ rom\\.\\ muscle\\ tone\\ regular\\.\\ \ \(0\)\
\-\ muscle\\ strength\\:\\ 5\\/5\\ throughout\ \(0\)\
\-\ neurologic\\:\ \(0\)\
\-\ cn\\ ii\\-xii\\ within\\ normal\\ limits\\.\\ reflexes\\ 4\\/4\\ bilaterally\\ throughout\\.\\ sensation\\ intact\\ to\\ light\\ touch\\,\\ and\\ pin\\ prick\\ on\\ upper\\ and\\ lower\\ extremities\\ bilaterally\\.\\ negative\\ babinski\\ reflex\\.\\ normal\\ gait\\.\\ \ \(0\)\
\-\ laboratory\\ data\\:\ \(0\)\
\-\ 03\\/19\\/13\\ \\-\\ 03\\/23\\/13\\ \\(initial\\ hospitalization\\)\ \(0\)\
\-\ cbc\\:\\ 03\\/19\\/13\\ plt\\ 6\ \(0\)\
\-\ cmp\\:\\ 03\\/19\\ \\-\\ 03\\/23\\ normal\\ gfr\ \(0\)\
\-\ immunology\\:\\ 03\\/20\\/13\\ ana\\ pos\\,\\ ssa\\ \\(ro\\)\\ h\\,\\ sm\\ \\(smith\\)\\ h\\,\\ ds\\-dna\\ h\\,\\ histone\\ ab\\ h\ \(0\)\
\-\ ua\\:\\ 3\\/21\\/13\\ negative\\ findings\ \(0\)\
\-\ 07\\/10\\/2017\\ \\(rheumatology\\ routine\\ labs\\)\ \(0\)\
\-\ urine\\ protein\\ creatinine\\ mass\\ ratio\\-\\ protein\\ total\\ random\\ urine\\-\\ high\\ 48\\,\\ protein\\/creatinine\\ ratio\\ high\\ 552\ \(0\)\
\-\ ua\\-\\ \\ hemoglobin\\ 2\\+\\,\\ protein\\ 2\\+\\ \ \(0\)\
\-\ 09\\/12\\/2017\\-\\ c3\\ serum\\ wnl\\,\\ and\\ c4\\ serum\\ high\ \(0\)\
\-\ 08\\/30\\/2017\ \(2\)\
\-\ renal\\ biopsy\\ report\\:\ \(0\)\
\-\ microscopic\\:\\ 3\\ core\\ bx\\ or\\ renal\\ cortex\\,\\ 2\\ cores\\ include\\ the\\ renal\\ capsule\\.\\ glomeruli\\-\\ 4\\/13\\ globally\\ sclerotic\\ \\(13\\%\\)\\,\\ normal\\ or\\ mildly\\ increased\\ in\\ size\\,\\ diffuse\\ mild\\-moderate\\ global\\ or\\ segmental\\ pas\\ positive\\ mesangial\\ expansion\\,\\ segmental\\ mild\\ mesangial\\ proliferation\\ in\\ 3\\ glomeruli\\,\\ cellular\\ crescents\\ in\\ 2\\ glomeruli\\,\\ fibrocellular\\ crescents\\ in\\ 3\\,\\ and\\ segmental\\ necrosis\\ without\\ crescent\\ formation\\ in\\ 1\\ glomerulus\\,\\ fibrous\\ crescent\\ in\\ 1\\ glomerulus\\.\\ tubulointerstitium\\-\\ well\\ circumscribed\\ zones\\ of\\ inflammation\\ with\\ lymphocytes\\,\\ plasma\\ cells\\,\\ and\\ rare\\ eosinophils\\ involving\\ estimated\\ 5\\-10\\ \\%\\ of\\ cortex\\,\\ foci\\ of\\ interstitial\\ pmn\\‚\\Ä\\ôs\\ adjacent\\ to\\ active\\ crescents\\,\\ interstitial\\ fibrosis\\ and\\ tubular\\ atrophy\\ in\\ 10\\-25\\%\\ cortex\\.\\ blood\\ vessels\\-\\ 3\\ small\\ interlobular\\ arteries\\ and\\ visible\\ periglomerular\\ arterioles\\ without\\ dx\\ pathological\\ changes\\.\ \(0\)\
\-\ immunofluorescence\\:\\ 10\\ glomeruli\\,\\ zero\\ \\%\\ globally\\ sclerotic\\;\\ iga\\ 1\\+\\ focal\\ segmental\\ granular\\ paramesangial\\/mesangial\\,\\ positive\\ epithelial\\ cells\\,\\ positive\\ protein\\ granules\\ and\\ casts\\;\\ igg\\ 1\\+\\ focal\\ segmental\\ granular\\ paramesangial\\/mesangial\\,\\ positive\\ protein\\ granules\\ and\\ casts\\,\\ positive\\ nuclear\\;\\ igm\\ 1\\+\\ granular\\ paramesangial\\/mesangial\\ and\\ segmental\\ capillary\\;\\ kappa\\ glomeruli\\ negative\\,\\ positive\\ casts\\;\\ lambda\\ glomeruli\\ negative\\,\\ positive\\ casts\\;\\ c1q\\ 1\\+\\ granular\\ paramesangial\\/mesangial\\;\\ c3\\ 1\\+\\ granular\\ paramesangial\\/mesangial\\;\\ albumin\\ and\\ fibrinogen\\ 1\\+\\ focal\\ segmental\\ glomerular\\ in\\ 3\\/10\\ glomeruli\\.\ \(0\)\
\-\ em\\:\\ 1\\ glomerulus\\.\\ mesangial\\ expansion\\ with\\ numerous\\ sized\\ electron\\ dense\\ deposits\\,\\ mesangial\\/paramesangial\\,\\ and\\ focal\\ subepithelial\\;\\ endocapillary\\ inflammatory\\ cells\\,\\ tubuloredicular\\ inclusions\\ in\\ glomerular\\ and\\ peritubular\\ capillary\\ endothelium\\;\\ epithelial\\ foot\\ process\\ simplification\\/effacement\\ with\\ incomplete\\ involvement\\ of\\ most\\ capillaries\\,\\ overall\\ involvement\\ estimated\\ 20\\-30\\%\\;\\ incomplete\\ loss\\ of\\ endothelial\\ fenestrations\\.\ \(0\)\
\-\ final\\ pathology\\ dx\\:\ \(0\)\
\-\ left\\ kidney\\-\\ percutaneous\\ needle\\ bx\ \(0\)\
\-\ active\\ and\\ sclerosing\\ immune\\ complex\\ gn\\ consistent\\ with\\ ln\\ isn\\/rps\\ class\\ 3\\ a\\/c\\;\\ cellular\\ crescents\\,\\ fibrocellular\\ crescents\\,\\ or\\ segmental\\ necrosis\\ are\\ identified\\ in\\ 20\\%\\ of\\ glomeruli\\.\ \(0\)\
\-\ comment\\-\\ unusual\\ features\\ include\\:\\ igm\\ dominant\\ fluorescence\\ and\\ presence\\ of\\ necrosis\\ and\\ crescent\\ formation\\ with\\ subendothelial\\ deposits\\.\\ these\\ features\\ taken\\ together\\ suggest\\ mechanism\\ of\\ autoimmune\\ injury\\ not\\ typical\\ of\\ ln\\.\ \(0\)\
\-\ patient\\ will\\ be\\ advised\\ to\\ continue\\ current\\ medication\\ regimen\\ of\\ mycophenolate\\ mofetil\\,\\ hydroxychloroquine\\ sulfate\\,\\ montelukast\\ sodium\\,\\ and\\ belimumab\\ for\\ her\\ current\\ medical\\ conditions\\.\\ it\\ is\\ imperative\\ that\\ the\\ patient\\ continues\\ with\\ her\\ immunosuppressive\\ therapy\\ of\\ mycophenolate\\ mofetil\\ to\\ adequately\\ treat\\ her\\ focal\\ lupus\\ nephritis\\ isn\\/rps\\ class\\ iii\\ a\\/c\\ and\\ prevent\\ relapse\\ with\\ recurrence\\ of\\ renal\\ inflammation\\ and\\ damage\\.\\ patient\\ will\\ be\\ advised\\ to\\ continue\\ hydroxychloroquine\\ sulfate\\ and\\ belimumab\\ medications\\ as\\ these\\ will\\ help\\ control\\ much\\ of\\ the\\ other\\ clinical\\ ailments\\ associated\\ with\\ sle\\ and\\ its\\ effects\\ on\\ multiple\\ organ\\ systems\\.\\ patient\\ has\\ noted\\ increased\\ asthma\\ symptoms\\ and\\ will\\ be\\ advised\\ to\\ continue\\ montelukast\\ sodium\\ as\\ prescribed\\ previously\\.\\ patient\\ is\\ now\\ in\\ the\\ maintenance\\ phase\\ of\\ therapy\\ for\\ her\\ focal\\ lupus\\ nephritis\\ and\\ will\\ be\\ advised\\ to\\ follow\\ up\\ every\\ 3\\ months\\ with\\ her\\ nephrologist\\ where\\ evaluation\\ to\\ monitor\\ ln\\ progression\\ will\\ consist\\ of\\ physical\\ exam\\,\\ urine\\ protein\\,\\ ua\\,\\ serum\\ c3\\ \\/\\ c4\\ \\/\\ anti\\-dna\\ levels\\,\\ cbc\\,\\ and\\ lft\\‚\\Ä\\ôs\\ will\\ ensue\\.\ \(0\)\
\-\ renal\\ ultrasound\ \(12\)\
\-\ clinical\\ indication\\:\\ \\ patient\\ with\\ hematuria\\,\\ microhematuria\\.\\ \\ icd\\-10\\ code\\ r31\\.9\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ real\\-time\\ renal\\ sonogram\\ was\\ performed\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ the\\ kidneys\\ appear\\ within\\ normal\\ limits\\ bilaterally\\.\\ there\\ are\\ no\\ renal\\ masses\\,\\ calculi\\ or\\ hydronephrosis\\.\\ there\\ are\\ no\\ perirenal\\ fluid\\ collections\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ right\\ kidney\\:\\ \\ measures\\ 12\\.7\\ x\\ 7\\.0\\ x\\ 5\\.0\\ cm\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ left\\ kidney\\:\\ \\ measures\\ 13\\.5\\ x\\ 5\\.1\\ x\\ 5\\.5\\ cm\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ there\\ is\\ no\\ aneurysmal\\ dilatation\\ of\\ the\\ abdominal\\ aorta\\ as\\ visualized\\.\\ the\\ inferior\\ vena\\ cava\\ is\\ unremarkable\\ as\\ visualized\\.\\ the\\ urinary\\ bladder\\ is\\ unremarkable\\ as\\ visualized\\.\\ the\\ ureteral\\ jets\\ were\\ demonstrated\\ bilaterally\\.\ \(0\)\
\-\ impression\\:\\ \\ unremarkable\\ renal\\ sonogram\\.\ \(0\)\
\-\ normal\\ renal\\ us\\ imaging\\ findings\\ of\\ the\\ right\\ kidney\\ will\\ be\\ discussed\\ with\\ patients\\ attached\\ images\\.\ \(0\)\
\-\ figure\\ titles\\ are\\ as\\ follows\\:\ \(0\)\
\-\ figure1\\.\\ 35\\ year\\-old\\ female\\ renal\\ us\\ \\(microhematuria\\)\ \(0\)\
\-\ figure\\ 2\\.\\ sagittal\\ us\\ midline\\ \\(inferior\\ vena\\ cava\\)\\ \ \(0\)\
\-\ figure\\ 3\\.\\ sagittal\\ midline\\ \\(aorta\\)\ \(0\)\
\-\ figure\\ 4\\.\\ transverse\\ midline\\ \\(aorta\\)\ \(0\)\
\-\ figure\\ 5\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 6\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 7\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 8\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 9\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 10\\.\\ left\\ lateral\\ decubitus\\ transverse\\ right\\ kidney\\ \\(superior\\ to\\ inferior\\)\ \(0\)\
\-\ figure\\ 11\\.\\ left\\ lateral\\ decubitus\\ transverse\\ right\\ kidney\\ \\(superior\\ to\\ inferior\\)\ \(0\)\
\-\ figure\\ 12\\.\\ left\\ lateral\\ decubitus\\ transverse\\ right\\ kidney\\ \\(superior\\ to\\ inferior\\)\ \(0\)\
\-\ figure\\ 13\\.\\ left\\ lateral\\ decubitus\\ transverse\\ right\\ kidney\\ \\(middle\\)\ \(0\)\
\-\ figure\\ 14\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(middle\\)\ \(0\)\
\-\ figure\\ 15\\.\\ transverse\\ bladder\ \(0\)\
\-\ figure\\ 16\\.\\ transverse\\ bladder\\ \\(right\\ jet\\)\ \(0\)\
\-\ see\\ captions\\ attached\\ to\\ each\\ figure\\ for\\ further\\ description\\.\ \(0\)\
\-\ sclerosing\\ immune\\ complex\\ glomerulonephritis\\ consistent\\ with\\ focal\\ lupus\\ nephritis\\ isn\\/rps\\ class\\ iii\\ a\\/c\ \(0\)\
\-\ 1\\)\\ focal\\ lupus\\ nephritis\ \(0\)\
\-\ 2\\)\\ c3\\ glomerulonephritis\ \(0\)\
\-\ 3\\)\\ post\\ streptococcal\\ glomerulonephritis\\ \ \(0\)\
\-\ 4\\)\\ iga\\ nephropthy\ \(0\)\
\-\ patient\\ is\\ a\\ 35\\-year\\-old\\ african\\ american\\ female\\ g1p1\\ with\\ a\\ previous\\ pmh\\ of\\ asthma\\ and\\ atopic\\ dermatitis\\ who\\ 4\\ years\\ ago\\ \\(3\\/19\\/2013\\)\\ initially\\ presented\\ to\\ the\\ ed\\ due\\ to\\ acute\\ onset\\ of\\ \\‚\\Ä\\údark\\ blueish\\ \\/\\ purple\\ spots\\ on\\ the\\ inside\\ of\\ her\\ mouth\\ and\\ red\\ bruises\\ on\\ her\\ arms\\‚\\Ä\\ù\\ with\\ no\\ recent\\ history\\ of\\ trauma\\ or\\ illness\\.\\ she\\ notes\\ that\\ while\\ in\\ the\\ ed\\ she\\ further\\ developed\\ \\‚\\Ä\\úpetechiae\\‚\\Ä\\ù\\ on\\ her\\ arms\\ and\\ legs\\.\\ patient\\‚\\Ä\\ôs\\ initial\\ lab\\ results\\ showed\\ thrombocytopenia\\ and\\ normocytic\\ anemia\\.\\ upon\\ further\\ workup\\ and\\ hospitalization\\ consisting\\ of\\ multiple\\ blood\\ transfusions\\ the\\ patient\\ was\\ diagnosed\\ with\\ itp\\ \\(idiopathic\\ thrombocytopenia\\ purpura\\ and\\ sle\\ \\ \\(systemic\\ lupus\\ erythematosus\\)\\.\\ she\\ was\\ started\\ on\\ a\\ tapered\\ course\\ of\\ prednisone\\ and\\ hydroxychloroquine\\ sulfate\\ and\\ later\\ followed\\ up\\ with\\ hematology\\ and\\ rheumatology\\.\\ \ \(0\)\
\-\ six\\ months\\ later\\ patient\\ experienced\\ a\\ 2\\ month\\ history\\ of\\ 2\\-6\\ \\/10\\ crampy\\,\\ non\\-radiating\\,\\ lower\\ back\\ \\/\\ buttocks\\ \\/\\ abdominal\\ pain\\,\\ which\\ upon\\ further\\ us\\ and\\ ct\\ imaging\\ and\\ eventual\\ surgery\\ found\\ to\\ be\\ due\\ to\\ a\\ mature\\ cystic\\ teratoma\\.\\ patient\\ underwent\\ left\\ oophorectomy\\ during\\ surgery\\.\\ of\\ note\\,\\ patient\\ also\\ has\\ had\\ hysterectomy\\ due\\ to\\ uterine\\ fibroids\\.\\ otherwise\\,\\ until\\ 07\\/10\\/2017\\ \\(4\\ years\\ after\\ dx\\ of\\ sle\\ and\\ itp\\)\\ patient\\‚\\Ä\\ôs\\ chronic\\ conditions\\ had\\ been\\ well\\ managed\\ with\\ hydroxychloroquine\\,\\ and\\ montelukast\\.\ \(0\)\
\-\ patient\\ states\\ that\\ after\\ routine\\ follow\\ up\\ with\\ her\\ rheumatologist\\ on\\ 07\\/10\\/2017\\ there\\ were\\ ua\\ findings\\ of\\ hematuria\\ and\\ proteinuria\\ \\(555\\ \\-\\ 650\\)\\ in\\ the\\ patient\\‚\\Ä\\ôs\\ urine\\.\\ she\\ was\\ referred\\ to\\ a\\ nephrologist\\ where\\ further\\ evaluation\\ through\\ us\\ imaging\\ and\\ biopsy\\ were\\ performed\\ on\\ 08\\/30\\/2017\\.\\ renal\\ biopsy\\ showed\\ new\\ diagnosis\\ of\\ glomerular\\ kidney\\ disease\\,\\ active\\ and\\ sclerosing\\ immune\\ complex\\ gn\\ consistent\\ with\\ ln\\ isn\\/rps\\ class\\ 3\\ a\\/c\\ \\.\\ patient\\ was\\ started\\ on\\ mycophenolate\\ mofetil\\ in\\ addition\\ to\\ her\\ previous\\ medications\\,\\ and\\ also\\ notes\\ a\\ course\\ of\\ tapered\\ prednisone\\.\\ patient\\ also\\ notes\\ that\\ she\\ had\\ begun\\ a\\ new\\ sle\\ medication\\,\\ belimumab\\,\\ during\\ late\\ august\\ 2017\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ review\\ of\\ systems\\:\ \(0\)\
\-\ patient\\ reports\\ fatigue\\,\\ photosensitivity\\,\\ photophobia\\,\\ heat\\ intolerance\\ \\(resulting\\ in\\ ha\\ and\\ nausea\\)\\,\\ and\\ painful\\ joints\\ \\(bl\\ knees\\ and\\ elbows\\)\\.\\ she\\ denies\\ fever\\,\\ loss\\ of\\ appetite\\,\\ dizziness\\,\\ insomnia\\,\\ weight\\ loss\\,\\ chills\\,\\ night\\ sweats\\,\\ chest\\ pain\\,\\ sob\\,\\ abdominal\\ pain\\,\\ urinary\\ frequency\\ \\/\\ urgency\\ \\/\\ pain\\,\\ constipation\\,\\ diarrhea\\,\\ weakness\\,\\ bruising\\,\\ bleeding\\,\\ weakness\\,\\ or\\ gross\\ neurologic\\ deficits\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ past\\ medical\\ history\\:\ \(0\)\
\-\ asthma\\,\\ atopic\\ dermatitis\\,\\ sle\\,\\ itp\\,\\ mature\\ cystic\\ teratoma\ \(0\)\
\-\ surgical\\ history\\:\ \(1\)\
\-\ hysterectomy\\,\\ left\\ oophorectomy\ \(0\)\
\-\ family\\ history\\:\ \(0\)\
\-\ maternal\\-\\ htn\\,\\ type\\ 2\\ dm\ \(0\)\
\-\ paternal\\-\\ sle\\,\\ breast\\ carcinoma\ \(0\)\
\-\ allergies\\:\ \(0\)\
\-\ reports\\ seafood\\,\\ tetanus\ \(0\)\
\-\ social\\ history\\:\ \(0\)\
\-\ works\\ in\\ medical\\ office\\,\\ and\\ lives\\ at\\ home\\ with\\ daughter\\.\\ never\\ a\\ smoker\\.\\ denies\\ ever\\ using\\ illicit\\ drugs\\.\\ \ \(0\)\
\-\ alcohol\\ use\\ of\\ 2\\-3\\ times\\ per\\ month\\.\ \(0\)\
\-\ medications\\:\ \(0\)\
\-\ mycophenolate\\ mofetil\\,\\ hydroxychloroquine\\ sulfate\\,\\ montelukast\\ sodium\\,\\ and\\ belimumab\\.\ \(0\)\
\-\ kidney\\ disease\\ is\\ often\\ referred\\ to\\ as\\ the\\ \\‚\\Ä\\úsilent\\ illness\\,\\‚\\Ä\\ù\\ as\\ often\\ patients\\ are\\ asymptomatic\\ in\\ the\\ earlier\\ stages\\,\\ and\\ by\\ the\\ time\\ they\\ do\\ become\\ symptomatic\\ they\\ already\\ have\\ severely\\ advanced\\ renal\\ disease\\.\\ due\\ to\\ this\\ renal\\ disease\\ plays\\ a\\ large\\ role\\ in\\ overall\\ morbidity\\ and\\ mortality\\,\\ and\\ throughout\\ the\\ past\\ few\\ decades\\ has\\ become\\ a\\ major\\ public\\ health\\ concern\\.\\ recent\\ statistics\\ from\\ the\\ nih\\ have\\ shown\\ that\\ renal\\ disease\\ is\\ responsible\\ for\\ more\\ deaths\\ in\\ a\\ year\\ than\\ breast\\ and\\ prostate\\ cancer\\ combined\\,\\ and\\ accounts\\ for\\ approximately\\ 50\\ billion\\ dollars\\ in\\ medicaid\\ spending\\ per\\ year\\ \\[1\\-3\\]\\.\\ although\\ the\\ incidence\\ of\\ the\\ disease\\ has\\ stabilized\\ over\\ the\\ past\\ few\\ years\\ it\\ still\\ has\\ a\\ substantial\\ prevalence\\ at\\ 14\\%\\ of\\ the\\ general\\ population\\,\\ which\\ is\\ why\\ awareness\\ for\\ disease\\ and\\ prevention\\ and\\ proactive\\ efforts\\ for\\ diagnosis\\ is\\ important\\.\\ it\\ is\\ important\\ to\\ first\\ understand\\ that\\ renal\\ disease\\ consists\\ of\\ a\\ wide\\ variety\\ of\\ disorders\\ \\(glomerular\\ disease\\,\\ tubular\\ disease\\,\\ vascular\\ disease\\ ect\\.\\)\\.\\ for\\ this\\ discussion\\ we\\ will\\ focus\\ on\\ glomerular\\ disease\\ \\(consisting\\ of\\ nephritic\\ and\\ nephrotic\\ conditions\\)\\,\\ specifically\\ focusing\\ on\\ lupus\\ nephritis\\ \\(ln\\)\\ and\\ c3\\ glomerulonephritis\\ \\(c3gn\\)\\ and\\ how\\ these\\ conditions\\ manifested\\ in\\ our\\ patient\\.\\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ what\\ is\\ interesting\\ about\\ our\\ patient\\'s\\ case\\ is\\ that\\ she\\ initially\\ presented\\ with\\ dark\\ blueish\\ \\/\\ purple\\ spots\\ on\\ the\\ inside\\ of\\ her\\ mouth\\ and\\ red\\ bruises\\ on\\ her\\ arms\\,\\ which\\ was\\ later\\ diagnosed\\ during\\ her\\ hospital\\ visit\\ as\\ itp\\ \\(immune\\ thrombocytopenic\\ purpura\\)\\.\\ primary\\ itp\\ is\\ an\\ autoimmune\\ process\\ in\\ which\\ auto\\-antibodies\\ are\\ produced\\ against\\ the\\ hosts\\ platelets\\.\\ these\\ antibodies\\ coat\\ host\\ platelets\\ and\\ damage\\ them\\ resulting\\ in\\ their\\ removal\\ by\\ the\\ spleen\\ resulting\\ in\\ thrombocytopenia\\ and\\ increased\\ bleeding\\ risk\\.\\ around\\ that\\ same\\ time\\ laboratory\\ findings\\ also\\ were\\ significant\\ for\\ a\\ diagnosis\\ of\\ sle\\ \\(systemic\\ lupus\\ erythematosus\\)\\.\\ traditionally\\ primary\\ itp\\ is\\ a\\ diagnosis\\ of\\ exclusion\\ if\\ there\\ is\\ only\\ findings\\ of\\ thrombocytopenia\\ without\\ any\\ other\\ findings\\ indicative\\ of\\ another\\ etiology\\.\\ with\\ this\\ being\\ said\\,\\ it\\ appears\\ that\\ our\\ patient\\ had\\ a\\ secondary\\ diagnosis\\ of\\ \\[sle\\]\\ associated\\ with\\ \\ itp\\.\\ the\\ diagnosis\\ of\\ sle\\ with\\ the\\ itp\\ co\\-morbidity\\ has\\ been\\ shown\\ to\\ be\\ rare\\ as\\ in\\ a\\ \\ recent\\ study\\ of\\ 152\\ patients\\ diagnosed\\ with\\ sle\\ there\\ was\\ reclassification\\ of\\ 12\\ individuals\\ having\\ secondary\\ itp\\ \\(8\\ percent\\)\\ during\\ the\\ two\\ years\\ of\\ evaluation\\ \\[4\\]\\.\\ although\\ the\\ patient\\ at\\ the\\ time\\ of\\ the\\ \\[sle\\]\\ associated\\ itp\\ diagnosis\\ had\\ no\\ laboratory\\ evidence\\ of\\ renal\\ disease\\,\\ the\\ likelihood\\ of\\ the\\ patient\\ to\\ develop\\ kidney\\ disease\\ in\\ the\\ future\\ has\\ been\\ reported\\ as\\ 50\\%\\ just\\ with\\ only\\ the\\ singular\\ diagnosis\\ of\\ sle\\.\\ no\\ studies\\ with\\ significant\\ data\\ could\\ be\\ found\\ to\\ support\\ increased\\ risk\\ of\\ renal\\ disease\\ with\\ both\\ sle\\ and\\ itp\\ diagnosis\\.\ \(0\)\
\-\ as\\ stated\\ previously\\,\\ it\\ is\\ important\\ for\\ those\\ at\\ risk\\ for\\ renal\\ disease\\ to\\ be\\ advised\\ about\\ preventative\\ measures\\,\\ proactive\\ screening\\ and\\ diagnostic\\ procedures\\ to\\ diagnose\\ renal\\ disease\\ in\\ its\\ earliest\\ stages\\ even\\ when\\ its\\ is\\ asymptomatic\\.\\ in\\ our\\ patient\\‚\\Ä\\ôs\\ case\\,\\ regular\\ follow\\ up\\ and\\ screening\\ with\\ her\\ rheumatologist\\ helped\\ identify\\ early\\ urinary\\ irregularities\\ \\(microhematuria\\ and\\ proteinuria\\ with\\ normal\\ gfr\\)\\.\\ this\\ allowed\\ for\\ further\\ evaluation\\ resulting\\ in\\ diagnosis\\.\\ the\\ evaluation\\ algorithm\\ for\\ hematuria\\ and\\ proteinuria\\ begins\\ with\\ serologic\\ testing\\,\\ then\\ imaging\\ \\(renal\\ us\\,\\ ct\\,\\ or\\ ivp\\)\\,\\ and\\ finally\\ biopsy\\,\\ \\(if\\ the\\ diagnosis\\ was\\ not\\ made\\ from\\ prior\\ studies\\)\\.\\ in\\ this\\ patient\\‚\\Ä\\ôs\\ case\\ serologic\\ testing\\ showed\\ supportive\\ findings\\ for\\ sle\\,\\ but\\ imaging\\ was\\ needed\\ to\\ rule\\ out\\ any\\ other\\ possible\\ diagnosis\\.\\ renal\\ us\\ was\\ performed\\ without\\ any\\ pathological\\ findings\\.\\ at\\ this\\ time\\ there\\ are\\ no\\ imaging\\ studies\\ that\\ can\\ accurately\\ diagnose\\ glomerular\\ disease\\.\\ a\\ renal\\ biopsy\\ was\\ needed\\ to\\ be\\ performed\\ for\\ not\\ only\\ a\\ clear\\ diagnosis\\,\\ but\\ also\\ the\\ fact\\ that\\ specific\\ diagnosis\\ and\\ classification\\ aids\\ in\\ therapeutic\\ decision\\ making\\ for\\ glomerular\\ disease\\.\\ prior\\ to\\ biopsy\\ a\\ plausible\\ nephritic\\ syndrome\\ \\(proteinuria\\ \\<\\ 3\\.5\\ g\\ per\\ day\\ or\\ 2\\+\\ or\\ less\\ on\\ urine\\ dipstick\\ analysis\\)\\ differential\\ diagnosis\\ consisted\\ of\\ \\ lupus\\ nephritis\\ \\(especially\\ in\\ the\\ context\\ of\\ a\\ sle\\ diagnosis\\)\\,\\ c3\\ glomerulonephritis\\ \\(a\\ rare\\ form\\ of\\ mpgn\\ but\\ not\\ out\\ of\\ reach\\ considering\\ the\\ laboratory\\ findings\\ and\\ possible\\ preceding\\ uri\\)\\,\\ post\\ streptococcal\\ glomerulonephritis\\ \\(considering\\ labs\\ and\\ possibility\\ of\\ preceding\\ uri\\)\\,\\ and\\ iga\\ nephropathy\\.\\ \ \(0\)\
\-\ it\\ was\\ not\\ surprising\\ that\\ the\\ biopsy\\ findings\\ were\\ indicative\\ of\\ lupus\\ nephritis\\ \\(specifically\\ \\-\\ sclerosing\\ immune\\ complex\\ glomerulonephritis\\ class\\ iii\\ a\\/c\\)\\.\\ the\\ following\\ findings\\ were\\ indicative\\ of\\ this\\ diagnosis\\:\\ glomeruli\\ 4\\/13\\ globally\\ sclerotic\\ \\(13\\%\\)\\ which\\ is\\ less\\ than\\ the\\ 50\\%\\ glomeruli\\ involvement\\ limit\\ on\\ lm\\;\\ \\ mesangial\\ expansion\\ with\\ numerous\\ sized\\ electron\\ dense\\ deposits\\ and\\ inclusions\\ in\\ glomerular\\ and\\ peritubular\\ capillary\\ endothelium\\ on\\ em\\;\\ and\\ class\\ a\\/c\\ findings\\ of\\ active\\ and\\ chronic\\ sclerosing\\ lesions\\.\\ \\ \ \(0\)\
\-\ ln\\ class\\ iii\\ a\\/c\\ description\\:\ \(0\)\
\-\ focal\\ lupus\\ nephritis\\ \\(class\\ iii\\)\\ \\-\\ hematuria\\ and\\ proteinuria\\ are\\ present\\,\\ with\\ possible\\ hypertension\\ decreased\\ gfr\\ and\\/or\\ nephrotic\\ syndrome\\.\\ histologic\\ findings\\ of\\ 50\\ percent\\ or\\ less\\ of\\ glomeruli\\ affected\\ on\\ light\\ microscopy\\,\\ im\\ shows\\ all\\ glomeruli\\ affected\\,\\ em\\ shows\\ mesangium\\ and\\ capillary\\ wall\\ subendothelial\\ deposits\\ \\[42\\]\\.\\ further\\ subclass\\ categories\\ of\\ class\\ iii\\ are\\ as\\ follows\\:\\ 1\\.\\ class\\ iii\\ \\(a\\)\\,\\ active\\ lesions\\,\\ focal\\ proliferative\\ lupus\\ nephritis\\ 2\\.\\ class\\ iii\\ \\(a\\/c\\)\\,\\ active\\ and\\ chronic\\ lesions\\,\\ focal\\ proliferative\\ and\\ sclerosing\\ lupus\\ nephritis\\ 3\\.class\\ iii\\ \\(c\\)\\,\\ chronic\\ inactive\\ lesions\\ with\\ scarring\\,\\ focal\\ sclerosing\\ lupus\\ nephritis\\ \\[7\\]\\.\\ \ \(0\)\
\-\ this\\ case\\ was\\ not\\ completely\\ straightforward\\ as\\ there\\ were\\ unusual\\ features\\ which\\ \\ include\\:\\ igm\\ dominant\\ fluorescence\\ and\\ presence\\ of\\ necrosis\\ and\\ crescent\\ formation\\ with\\ subendothelial\\ deposits\\;\\ these\\ features\\ taken\\ together\\ suggest\\ mechanism\\ of\\ autoimmune\\ injury\\ not\\ typical\\ of\\ ln\\.\\ c3gn\\ is\\ a\\ subclass\\ of\\ mpgn\\ which\\ has\\ em\\ findings\\ of\\ subendothelial\\ and\\ mesangial\\ electron\\-dense\\ deposits\\ possibly\\ similar\\ to\\ what\\ is\\ seen\\ in\\ addition\\ to\\ the\\ ln\\ findings\\ \\[5\\,6\\]\\.\\ if\\ this\\ is\\ the\\ case\\ the\\ question\\ is\\ how\\ does\\ this\\ affect\\ overall\\ management\\?\\ surprisingly\\,\\ the\\ recommended\\ non\\-immunosuppressive\\ agents\\ \\(acei\\,\\ arb\\,\\ and\\ lipid\\ lowering\\ agents\\)\\ and\\ immunosuppressives\\ are\\ the\\ same\\.\\ there\\ has\\ been\\ some\\ debate\\ about\\ the\\ effectiveness\\ of\\ immunosuppressive\\ therapy\\,\\ but\\ in\\ a\\ recent\\ retrospective\\ cohort\\ study\\ of\\ 60\\ c3gn\\ patients\\ the\\ immunotherapy\\ combination\\ of\\ mycophenolate\\ mofetil\\ and\\ glucocorticoids\\ was\\ found\\ to\\ be\\ therapeutically\\ effective\\ in\\ c3gn\\ \\[8\\]\\.\\ immunosuppressive\\ therapy\\ consists\\ of\\ aggressive\\ induction\\ and\\ less\\ aggressive\\ maintenance\\ phases\\.\\ patient\\ is\\ in\\ maintenance\\ phase\\ with\\ stable\\ disease\\ and\\ currently\\ following\\ up\\ with\\ the\\ nephrologist\\ every\\ few\\ months\\ for\\ routine\\ examination\\.\\ \ \(0\)\
\-\ the\\ prognosis\\ of\\ either\\ ln\\ or\\ c3gn\\ varies\\ amongst\\ patients\\,\\ but\\ both\\ carry\\ the\\ risk\\ of\\ renal\\ disease\\ progression\\ to\\ esrd\\.\\ reassuringly\\,\\ what\\ has\\ been\\ noted\\ in\\ both\\ diseases\\ is\\ that\\ early\\ administration\\ of\\ non\\-immunosuppressive\\ and\\ immunosuppressive\\ therapies\\ have\\ greatly\\ reduced\\ the\\ rate\\ of\\ progression\\ to\\ esrd\\.\\ interestingly\\,\\ there\\ were\\ not\\ many\\ records\\ or\\ studies\\ of\\ patients\\ with\\ both\\ ln\\ and\\ c3gn\\ documented\\.\\ possible\\ further\\ investigation\\ should\\ be\\ performed\\ into\\ the\\ incidence\\ of\\ having\\ both\\ ln\\ and\\ c3gn\\ disease\\ and\\ its\\ associated\\ variety\\ of\\ clinical\\ symptoms\\,\\ risk\\ factors\\,\\ and\\ prognosis\\ would\\ be\\ informative\\.\\ \\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ xu\\ jq\\,\\ murphy\\ sl\\,\\ kochanek\\ kd\\,\\ bastian\\ ba\\.\\ deaths\\:\\ final\\ data\\ for\\ 2013\\.\\ www\\.cdc\\.gov\\ \\.\\ published\\ february\\ 16\\,\\ 2016\\.\\ accessed\\ december\\ 6\\,\\ 2016\\.\\ \ \(0\)\
\-\ 2\\.\\ centers\\ for\\ disease\\ control\\ and\\ prevention\\.\\ age\\-adjusted\\ prevalence\\ of\\ ckd\\ stages\\ 1\\-4\\ by\\ gender\\ 1999\\-2012\\.\\ chronic\\ kidney\\ disease\\ \\(ckd\\)\\ surveillance\\ project\\ website\\.\\ https\\:\\/\\/nccd\\.cdc\\.gov\\ \\.\\ accessed\\ december\\ 6\\,\\ 2016\\.\\ \ \(0\)\
\-\ 3\\.\\ centers\\ for\\ disease\\ control\\ and\\ prevention\\.\\ age\\-adjusted\\ prevalence\\ of\\ ckd\\ stages\\ 1\\-4\\ by\\ race\\/ethnicity\\ 1999\\-2012\\.\\ chronic\\ kidney\\ disease\\ \\(ckd\\)\\ surveillance\\ project\\ website\\.\\ https\\:\\/\\/nccd\\.cdc\\.gov\\ \\.\\ accessed\\ december\\ 6\\,\\ 2016\\.\ \(0\)\
\-\ 4\\.\\ portielje\\ je\\,\\ westendorp\\ rg\\,\\ kluin\\-nelemans\\ hc\\,\\ brand\\ a\\.\\ morbidity\\ and\\ mortality\\ in\\ adults\\ with\\ idiopathic\\ thrombocytopenic\\ purpura\\.\\ blood\\ 2001\\;\\ 97\\:2549\\.\ \(0\)\
\-\ 5\\.\\ fakhouri\\ f\\,\\ fr\\√\\©meaux\\-bacchi\\ v\\,\\ no\\√\\´l\\ lh\\,\\ et\\ al\\.\\ c3\\ glomerulopathy\\:\\ a\\ new\\ classification\\.\\ nat\\ rev\\ nephrol\\ 2010\\;\\ 6\\:494\\.\ \(0\)\
\-\ 6\\.\\ bomback\\ as\\,\\ appel\\ gb\\.\\ pathogenesis\\ of\\ the\\ c3\\ glomerulopathies\\ and\\ reclassification\\ of\\ mpgn\\.\\ nat\\ rev\\ nephrol\\ 2012\\;\\ 8\\:634\\.\ \(0\)\
\-\ 7\\.\\ smet\\ ad\\,\\ kuypers\\ d\\,\\ evenepoel\\ p\\,\\ et\\ al\\.\\ \\'full\\ house\\'\\ positive\\ immunohistochemical\\ membranoproliferative\\ glomerulonephritis\\ in\\ a\\ patient\\ with\\ portosystemic\\ shunt\\.\\ nephrol\\ dial\\ transplant\\ 2001\\;\\ 16\\:2258\\.\ \(0\)\
\-\ 8\\.\\ rabasco\\ c\\,\\ cavero\\ t\\,\\ rom\\√\\°n\\ e\\,\\ et\\ al\\.\\ effectiveness\\ of\\ mycophenolate\\ mofetil\\ in\\ c3\\ glomerulonephritis\\.\\ kidney\\ int\\ 2015\\;\\ 88\\:1153\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ and\\:\\ 0\\.21656115339447507\ \(0\)\
\-\ glomeruli\\:\\ 0\\.18303130133043866\ \(0\)\
\-\ mesangial\\:\\ 0\\.17558275165015017\ \(0\)\
\-\ figure\\:\\ 0\\.17119280081774688\ \(0\)\
\-\ itp\\:\\ 0\\.16777869288623543\ \(0\)\
\-\ of\\:\\ 0\\.16602806496268865\ \(0\)\
\-\ ln\\:\\ 0\\.1622416250748676\ \(0\)\
\-\ sle\\:\\ 0\\.15890644541176033\ \(0\)\
\-\ nephritis\\:\\ 0\\.14663350754703813\ \(0\)\
\-\ renal\\:\\ 0\\.14295784299954165\ \(0\)\
\-\ kidney\\:\\ 0\\.14024278328754675\ \(0\)\
\-\ class\\:\\ 0\\.1393694325386049\ \(0\)\
\-\ lupus\\:\\ 0\\.13521676596421534\ \(0\)\
\-\ decubitus\\:\\ 0\\.11847765048120225\ \(0\)\
\-\ the\\:\\ 0\\.11551312785614398\ \(0\)\
\-\ glomerulonephritis\\:\\ 0\\.11418205382305327\ \(0\)\
\-\ glomerular\\:\\ 0\\.11231823004432938\ \(0\)\
\-\ c3gn\\:\\ 0\\.11173447832282282\ \(0\)\
\-\ in\\:\\ 0\\.109251642751333\ \(0\)\
\-\ disease\\:\\ 0\\.10893328649442896\ \(0\)\
\-\ to\\:\\ 0\\.09981094449055149\ \(0\)\
\-\ mycophenolate\\:\\ 0\\.09577240999099099\ \(0\)\
\-\ mofetil\\:\\ 0\\.09577240999099099\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0879608776453078\ \(0\)\
\-\ patient\\:\\ 0\\.08765211067433695\ \(0\)\
\-\ her\\:\\ 0\\.0872993884778469\ \(0\)\
\-\ c3\\:\\ 0\\.08679499765466951\ \(0\)\
\-\ regular\\:\\ 0\\.08618042020822153\ \(0\)\
\-\ immunosuppressive\\:\\ 0\\.08423867253324703\ \(0\)\
\-\ 13\\:\\ 0\\.08280593844391607\ \(0\)\
\-\ with\\:\\ 0\\.08208641413013584\ \(0\)\
\-\ iii\\:\\ 0\\.07756237818739938\ \(0\)\
\-\ crescents\\:\\ 0\\.0762630422210161\ \(0\)\
\-\ segmental\\:\\ 0\\.07571416161664118\ \(0\)\
\-\ lateral\\:\\ 0\\.0743015534582677\ \(0\)\
\-\ findings\\:\\ 0\\.07389163739869253\ \(0\)\
\-\ sclerosing\\:\\ 0\\.07359950877646258\ \(0\)\
\-\ or\\:\\ 0\\.0729177185940605\ \(0\)\
\-\ hydroxychloroquine\\:\\ 0\\.0717939734603799\ \(0\)\
\-\ focal\\:\\ 0\\.07164343772117103\ \(0\)\
\-\ is\\:\\ 0\\.06833530008679577\ \(0\)\
\-\ deposits\\:\\ 0\\.06806637148252075\ \(0\)\
\-\ protein\\:\\ 0\\.0648404988305317\ \(0\)\
\-\ subendothelial\\:\\ 0\\.06384827332732733\ \(0\)\
\-\ belimumab\\:\\ 0\\.06384827332732733\ \(0\)\
\-\ proteinuria\\:\\ 0\\.0634344743461407\ \(0\)\
\-\ sagittal\\:\\ 0\\.06139949170632311\ \(0\)\
\-\ montelukast\\:\\ 0\\.06101043377681288\ \(0\)\
\-\ for\\:\\ 0\\.06050433791091725\ \(0\)\
\-\ as\\:\\ 0\\.06014687068135282\ \(0\)\
\-\ granular\\:\\ 0\\.06011442708452574\ \(0\)\
\-\ ckd\\:\\ 0\\.05899695457267914\ \(0\)\
\-\ 10\\:\\ 0\\.05836482963811677\ \(0\)\
\-\ will\\:\\ 0\\.05781734908587347\ \(0\)\
\-\ that\\:\\ 0\\.05630891132654642\ \(0\)\
\-\ casts\\:\\ 0\\.05615911502216469\ \(0\)\
\-\ us\\:\\ 0\\.05557686295702658\ \(0\)\
\-\ immune\\:\\ 0\\.055553747885918194\ \(0\)\
\-\ advised\\:\\ 0\\.055553747885918194\ \(0\)\
\-\ sulfate\\:\\ 0\\.054145635818030946\ \(0\)\
\-\ transverse\\:\\ 0\\.05383246962958457\ \(0\)\
\-\ be\\:\\ 0\\.05263651651790507\ \(0\)\
\-\ positive\\:\\ 0\\.05261664244606484\ \(0\)\
\-\ bl\\:\\ 0\\.052583860013655725\ \(0\)\
\-\ em\\:\\ 0\\.052583860013655725\ \(0\)\
\-\ further\\:\\ 0\\.05200724267942147\ \(0\)\
\-\ thrombocytopenia\\:\\ 0\\.051916786590057454\ \(0\)\
\-\ on\\:\\ 0\\.0512462540402636\ \(0\)\
\-\ crescent\\:\\ 0\\.049294317063382755\ \(0\)\
\-\ biopsy\\:\\ 0\\.04897512405430422\ \(0\)\
\-\ normal\\:\\ 0\\.04890295149124304\ \(0\)\
\-\ was\\:\\ 0\\.04869952590353642\ \(0\)\
\-\ no\\:\\ 0\\.04868645767960733\ \(0\)\
\-\ glomerulus\\:\\ 0\\.04788620499549549\ \(0\)\
\-\ mpgn\\:\\ 0\\.04788620499549549\ \(0\)\
\-\ left\\:\\ 0\\.047667140590318124\ \(0\)\
\-\ globally\\:\\ 0\\.045757825332609664\ \(0\)\
\-\ nephrologist\\:\\ 0\\.045757825332609664\ \(0\)\
\-\ has\\:\\ 0\\.04559108941472014\ \(0\)\
\-\ urine\\:\\ 0\\.044672143703339995\ \(0\)\
\-\ 2016\\:\\ 0\\.04466520660718679\ \(0\)\
\-\ active\\:\\ 0\\.04447081626292268\ \(0\)\
\-\ nephrol\\:\\ 0\\.04424771592950935\ \(0\)\
\-\ right\\:\\ 0\\.043019233228792135\ \(0\)\
\-\ stages\\:\\ 0\\.04270839956296879\ \(0\)\
\-\ electron\\:\\ 0\\.042119336266623515\ \(0\)\
\-\ capillary\\:\\ 0\\.041903032372094876\ \(0\)\
\-\ she\\:\\ 0\\.04159088088977641\ \(0\)\
\-\ were\\:\\ 0\\.04116004966838956\ \(0\)\
\-\ lesions\\:\\ 0\\.040126105631689404\ \(0\)\
\-\ gfr\\:\\ 0\\.03999095660373767\ \(0\)\
\-\ there\\:\\ 0\\.03971477709951305\ \(0\)\
\-\ iga\\:\\ 0\\.03893758994254309\ \(0\)\
\-\ ua\\:\\ 0\\.03811794231315373\ \(0\)\
\-\ purpura\\:\\ 0\\.03806068460768443\ \(0\)\
\-\ are\\:\\ 0\\.037874011643180286\ \(0\)\
\-\ igm\\:\\ 0\\.03767167480724652\ \(0\)\
\-\ microhematuria\\:\\ 0\\.03767167480724652\ \(0\)\
\-\ maintenance\\:\\ 0\\.03730951534735595\ \(0\)\
\-\ prevention\\:\\ 0\\.03665250520596762\ \(0\)\
\-\ conditions\\:\\ 0\\.03646812794533591\ \(0\)\
\-\ expansion\\:\\ 0\\.03639848584328778\ \(0\)\
\-\ december\\:\\ 0\\.03635246753775153\ \(0\)\
\-\ risk\\:\\ 0\\.035658666927372955\ \(0\)\
\-\ chronic\\:\\ 0\\.03554723367632818\ \(0\)\
\-\ our\\:\\ 0\\.03536926286658727\ \(0\)\
\-\ hematuria\\:\\ 0\\.03530969677505739\ \(0\)\
\-\ sodium\\:\\ 0\\.034842358134651225\ \(0\)\
\-\ notes\\:\\ 0\\.03462807409097422\ \(0\)\
\-\ this\\:\\ 0\\.03429710745418026\ \(0\)\
\-\ inferior\\:\\ 0\\.03395178103438427\ \(0\)\
\-\ accessed\\:\\ 0\\.03384898332794148\ \(0\)\
\-\ patients\\:\\ 0\\.033689733667299965\ \(0\)\
\-\ dx\\:\\ 0\\.0336710262813698\ \(0\)\
\-\ autoimmune\\:\\ 0\\.033498904955390096\ \(0\)\
\-\ resulting\\:\\ 0\\.03322246585045742\ \(0\)\
\-\ prevalence\\:\\ 0\\.03271397847176539\ \(0\)\
\-\ 2012\\:\\ 0\\.03271397847176539\ \(0\)\
\-\ medial\\:\\ 0\\.03248493267566117\ \(0\)\
\-\ morbidity\\:\\ 0\\.032160916878269497\ \(0\)\
\-\ features\\:\\ 0\\.03212472954737595\ \(0\)\
\-\ fibrocellular\\:\\ 0\\.031924136663663664\ \(0\)\
\-\ peritubular\\:\\ 0\\.031924136663663664\ \(0\)\
\-\ blueish\\:\\ 0\\.031924136663663664\ \(0\)\
\-\ proactive\\:\\ 0\\.031924136663663664\ \(0\)\
\-\ nephritic\\:\\ 0\\.031924136663663664\ \(0\)\
\-\ reclassification\\:\\ 0\\.031924136663663664\ \(0\)\
\-\ which\\:\\ 0\\.03176977029396408\ \(0\)\
\-\ without\\:\\ 0\\.031588160561413614\ \(0\)\
\-\ not\\:\\ 0\\.03152263698493058\ \(0\)\
\-\ imaging\\:\\ 0\\.03147266478422742\ \(0\)\
\-\ visualized\\:\\ 0\\.031176050239616105\ \(0\)\
\-\ 16\\:\\ 0\\.03111063879613114\ \(0\)\
\-\ indicative\\:\\ 0\\.030783706475712134\ \(0\)\
\-\ complex\\:\\ 0\\.030761411216905468\ \(0\)\
\-\ it\\:\\ 0\\.03065533732989186\ \(0\)\
\-\ necrosis\\:\\ 0\\.03051794411193908\ \(0\)\
\-\ inclusions\\:\\ 0\\.03050521688840644\ \(0\)\
\-\ gn\\:\\ 0\\.03050521688840644\ \(0\)\
\-\ fluorescence\\:\\ 0\\.03050521688840644\ \(0\)\
\-\ subclass\\:\\ 0\\.03050521688840644\ \(0\)\
\-\ evaluation\\:\\ 0\\.03043539582235256\ \(0\)\
\-\ arms\\:\\ 0\\.03021049426195533\ \(0\)\
\-\ midline\\:\\ 0\\.030027093335199224\ \(0\)\
\-\ asthma\\:\\ 0\\.029860415889403955\ \(0\)\
\-\ time\\:\\ 0\\.029580464317367463\ \(0\)\
\-\ its\\:\\ 0\\.029542355345067554\ \(0\)\
\-\ mouth\\:\\ 0\\.02953223214768495\ \(0\)\
\-\ performed\\:\\ 0\\.02952447233817483\ \(0\)\
\-\ atopic\\:\\ 0\\.02949847728633957\ \(0\)\
\-\ nat\\:\\ 0\\.02949847728633957\ \(0\)\
\-\ data\\:\\ 0\\.02937552707399533\ \(0\)\
\-\ continue\\:\\ 0\\.02937552707399533\ \(0\)\
\-\ studies\\:\\ 0\\.029286889996861496\ \(0\)\
\-\ been\\:\\ 0\\.029075721827408495\ \(0\)\
\-\ laboratory\\:\\ 0\\.028992152826467\ \(0\)\
\-\ what\\:\\ 0\\.028791678118743152\ \(0\)\
\-\ granules\\:\\ 0\\.02871758938415196\ \(0\)\
\-\ endothelium\\:\\ 0\\.02871758938415196\ \(0\)\
\-\ purple\\:\\ 0\\.02871758938415196\ \(0\)\
\-\ these\\:\\ 0\\.028181833711396737\ \(0\)\
\-\ streptococcal\\:\\ 0\\.028079557511082345\ \(0\)\
\-\ nephrotic\\:\\ 0\\.028079557511082345\ \(0\)\
\-\ serologic\\:\\ 0\\.028079557511082345\ \(0\)\
\-\ 50\\:\\ 0\\.02788240111526871\ \(0\)\
\-\ both\\:\\ 0\\.027829961209616682\ \(0\)\
\-\ tapered\\:\\ 0\\.02754010924882178\ \(0\)\
\-\ rheumatologist\\:\\ 0\\.02754010924882178\ \(0\)\
\-\ deaths\\:\\ 0\\.02754010924882178\ \(0\)\
\-\ thrombocytopenic\\:\\ 0\\.02754010924882178\ \(0\)\
\-\ overall\\:\\ 0\\.027510983348722238\ \(0\)\
\-\ progression\\:\\ 0\\.027457144618997537\ \(0\)\
\-\ 12\\:\\ 0\\.027292250571288094\ \(0\)\
\-\ less\\:\\ 0\\.027161424827507417\ \(0\)\
\-\ esrd\\:\\ 0\\.027072817909015473\ \(0\)\
\-\ project\\:\\ 0\\.027072817909015473\ \(0\)\
\-\ possible\\:\\ 0\\.027051202494275516\ \(0\)\
\-\ recent\\:\\ 0\\.027032999692053857\ \(0\)\
\-\ serum\\:\\ 0\\.02685079089130323\ \(0\)\
\-\ rev\\:\\ 0\\.026660637735825117\ \(0\)\
\-\ bilaterally\\:\\ 0\\.02662689237218293\ \(0\)\
\-\ dense\\:\\ 0\\.026394048149397508\ \(0\)\
\-\ petechiae\\:\\ 0\\.026291930006827863\ \(0\)\
\-\ preceding\\:\\ 0\\.026291930006827863\ \(0\)\
\-\ effectiveness\\:\\ 0\\.026291930006827863\ \(0\)\
\-\ bx\\:\\ 0\\.025958393295028727\ \(0\)\
\-\ website\\:\\ 0\\.025958393295028727\ \(0\)\
\-\ urinary\\:\\ 0\\.025893743081698808\ \(0\)\
\-\ any\\:\\ 0\\.025802532025802218\ \(0\)\
\-\ control\\:\\ 0\\.025584875756006663\ \(0\)\
\-\ few\\:\\ 0\\.025400673342687766\ \(0\)\
\-\ bruises\\:\\ 0\\.025373789738456286\ \(0\)\
\-\ important\\:\\ 0\\.025364596017638037\ \(0\)\
\-\ during\\:\\ 0\\.025288210307909436\ \(0\)\
\-\ sclerotic\\:\\ 0\\.025118767748223646\ \(0\)\
\-\ medications\\:\\ 0\\.025118767748223646\ \(0\)\
\-\ rheumatology\\:\\ 0\\.02511444987149768\ \(0\)\
\-\ oophorectomy\\:\\ 0\\.02511444987149768\ \(0\)\
\-\ proliferative\\:\\ 0\\.02511444987149768\ \(0\)\
\-\ case\\:\\ 0\\.025072163576699513\ \(0\)\
\-\ had\\:\\ 0\\.024864936529708632\ \(0\)\
\-\ per\\:\\ 0\\.024851233156808317\ \(0\)\
\-\ negative\\:\\ 0\\.02471710356099447\ \(0\)\
\-\ up\\:\\ 0\\.02468655057993686\ \(0\)\
\-\ but\\:\\ 0\\.024678527913729206\ \(0\)\
\-\ antibodies\\:\\ 0\\.024647158531691377\ \(0\)\
\-\ years\\:\\ 0\\.024473301649000384\ \(0\)\
\-\ uri\\:\\ 0\\.024435003470645082\ \(0\)\
\-\ measures\\:\\ 0\\.024413543902725245\ \(0\)\
\-\ cortex\\:\\ 0\\.0243836336785985\ \(0\)\
\-\ aorta\\:\\ 0\\.02432431971268331\ \(0\)\
\-\ spots\\:\\ 0\\.024234978358501018\ \(0\)\
\-\ dermatitis\\:\\ 0\\.024045770833810296\ \(0\)\
\-\ al\\:\\ 0\\.023791941856009812\ \(0\)\
\-\ formation\\:\\ 0\\.023738918878592977\ \(0\)\
\-\ sonogram\\:\\ 0\\.023695530096240452\ \(0\)\
\-\ inside\\:\\ 0\\.023695530096240452\ \(0\)\
\-\ erythematosus\\:\\ 0\\.023695530096240452\ \(0\)\
\-\ limits\\:\\ 0\\.02366037531647969\ \(0\)\
\-\ also\\:\\ 0\\.02347428833020991\ \(0\)\
\-\ et\\:\\ 0\\.023456496093120827\ \(0\)\
\-\ centers\\:\\ 0\\.023377175563371537\ \(0\)\
\-\ bladder\\:\\ 0\\.0232362163547522\ \(0\)\
\-\ hysterectomy\\:\\ 0\\.02322823875643415\ \(0\)\
\-\ routine\\:\\ 0\\.0231884957521704\ \(0\)\
\-\ cellular\\:\\ 0\\.02308538272731615\ \(0\)\
\-\ cells\\:\\ 0\\.0230710584126791\ \(0\)\
\-\ due\\:\\ 0\\.022949460753260615\ \(0\)\
\-\ therapy\\:\\ 0\\.022939324656617046\ \(0\)\
\-\ history\\:\\ 0\\.02288031512933713\ \(0\)\
\-\ pink\\:\\ 0\\.022816058583243794\ \(0\)\
\-\ description\\:\\ 0\\.022816058583243794\ \(0\)\
\-\ rare\\:\\ 0\\.022604646796918225\ \(0\)\
\-\ together\\:\\ 0\\.02256598888529432\ \(0\)\
\-\ platelets\\:\\ 0\\.02256598888529432\ \(0\)\
\-\ about\\:\\ 0\\.022416781533592483\ \(0\)\
\-\ diagnose\\:\\ 0\\.022332603303593396\ \(0\)\
\-\ consisting\\:\\ 0\\.022221499154367278\ \(0\)\
\-\ throughout\\:\\ 0\\.022021916484213023\ \(0\)\
\-\ hospitalization\\:\\ 0\\.022009344093320983\ \(0\)\
\-\ https\\:\\ 0\\.022009344093320983\ \(0\)\
\-\ surveillance\\:\\ 0\\.021809318981176926\ \(0\)\
\-\ diagnosed\\:\\ 0\\.02169027589012555\ \(0\)\
\-\ involvement\\:\\ 0\\.021672451662025475\ \(0\)\
\-\ considering\\:\\ 0\\.021620111456486197\ \(0\)\
\-\ increased\\:\\ 0\\.021589374707411516\ \(0\)\
\-\ epithelial\\:\\ 0\\.021440611252179664\ \(0\)\
\-\ later\\:\\ 0\\.02142906627474292\ \(0\)\
\-\ mature\\:\\ 0\\.021354199781484395\ \(0\)\
\-\ attached\\:\\ 0\\.021187526054901377\ \(0\)\
\-\ variety\\:\\ 0\\.02110707454038053\ \(0\)\
\-\ how\\:\\ 0\\.02110707454038053\ \(0\)\
\-\ associated\\:\\ 0\\.021043306356542554\ \(0\)\
\-\ prednisone\\:\\ 0\\.02102843107898931\ \(0\)\
\-\ agents\\:\\ 0\\.020876255505736012\ \(0\)\
\-\ pathological\\:\\ 0\\.02080257937911005\ \(0\)\
\-\ estimated\\:\\ 0\\.020730422456655788\ \(0\)\
\-\ new\\:\\ 0\\.02071540385242105\ \(0\)\
\-\ classification\\:\\ 0\\.020522470983808088\ \(0\)\
\-\ sized\\:\\ 0\\.020390399205919698\ \(0\)\
\-\ creatinine\\:\\ 0\\.020326186638192918\ \(0\)\
\-\ rubs\\:\\ 0\\.020080507764852793\ \(0\)\
\-\ illness\\:\\ 0\\.020080507764852793\ \(0\)\
\-\ specifically\\:\\ 0\\.020080507764852793\ \(0\)\
\-\ unremarkable\\:\\ 0\\.02007411782702964\ \(0\)\
\-\ ratio\\:\\ 0\\.020021691476922437\ \(0\)\
\-\ showed\\:\\ 0\\.019944500620986735\ \(0\)\
\-\ c4\\:\\ 0\\.01985095094365913\ \(0\)\
\-\ consists\\:\\ 0\\.01985095094365913\ \(0\)\
\-\ percent\\:\\ 0\\.019741583081620478\ \(0\)\
\-\ mortality\\:\\ 0\\.019635529912469526\ \(0\)\
\-\ incomplete\\:\\ 0\\.019583684715996887\ \(0\)\
\-\ final\\:\\ 0\\.019583684715996887\ \(0\)\
\-\ dark\\:\\ 0\\.019583684715996887\ \(0\)\
\-\ follows\\:\\ 0\\.01953259641079021\ \(0\)\
\-\ past\\:\\ 0\\.019490959605396704\ \(0\)\
\-\ superior\\:\\ 0\\.0194675255033883\ \(0\)\
\-\ damage\\:\\ 0\\.019432604272389378\ \(0\)\
\-\ found\\:\\ 0\\.019374821458099857\ \(0\)\
\-\ every\\:\\ 0\\.019335390055749455\ \(0\)\
\-\ 20\\:\\ 0\\.019317701959435975\ \(0\)\
\-\ systems\\:\\ 0\\.019287777256593225\ \(0\)\
\-\ vena\\:\\ 0\\.019287777256593225\ \(0\)\
\-\ cava\\:\\ 0\\.0191944520791621\ \(0\)\
\-\ medical\\:\\ 0\\.019030303907564862\ \(0\)\
\-\ clinical\\:\\ 0\\.018976794472427453\ \(0\)\
\-\ rom\\:\\ 0\\.018886121863530215\ \(0\)\
\-\ at\\:\\ 0\\.018850076762604875\ \(0\)\
\-\ 2001\\:\\ 0\\.018844211341592258\ \(0\)\
\-\ mechanism\\:\\ 0\\.018802796813809274\ \(0\)\
\-\ red\\:\\ 0\\.018802796813809274\ \(0\)\
\-\ only\\:\\ 0\\.01870701181668148\ \(0\)\
\-\ dominant\\:\\ 0\\.018681415163056433\ \(0\)\
\-\ medication\\:\\ 0\\.018450596128411916\ \(0\)\
\-\ loss\\:\\ 0\\.01824268895774472\ \(0\)\
\-\ interstitial\\:\\ 0\\.018096811606483992\ \(0\)\
\-\ african\\:\\ 0\\.018030152700485937\ \(0\)\
\-\ appreciated\\:\\ 0\\.017997293428502998\ \(0\)\
\-\ testing\\:\\ 0\\.01793248626613465\ \(0\)\
\-\ unusual\\:\\ 0\\.01790052726086882\ \(0\)\
\-\ include\\:\\ 0\\.017816120958100895\ \(0\)\
\-\ systemic\\:\\ 0\\.017714670130646124\ \(0\)\
\-\ become\\:\\ 0\\.017714670130646124\ \(0\)\
\-\ prognosis\\:\\ 0\\.017566990549069683\ \(0\)\
\-\ current\\:\\ 0\\.0174812845489452\ \(0\)\
\-\ months\\:\\ 0\\.017429550391039512\ \(0\)\
\-\ if\\:\\ 0\\.017397928427145867\ \(0\)\
\-\ blood\\:\\ 0\\.017390052611517135\ \(0\)\
\-\ tubular\\:\\ 0\\.017342946902320057\ \(0\)\
\-\ light\\:\\ 0\\.01728910758262145\ \(0\)\
\-\ teratoma\\:\\ 0\\.017262495387799205\ \(0\)\
\-\ aggressive\\:\\ 0\\.017262495387799205\ \(0\)\
\-\ having\\:\\ 0\\.01720987053514543\ \(0\)\
\-\ incidence\\:\\ 0\\.017183851926407985\ \(0\)\
\-\ joints\\:\\ 0\\.017158025338672788\ \(0\)\
\-\ phase\\:\\ 0\\.01708166987131832\ \(0\)\
\-\ american\\:\\ 0\\.017031676353154692\ \(0\)\
\-\ high\\:\\ 0\\.017017934052078746\ \(0\)\
\-\ by\\:\\ 0\\.016954339535897728\ \(0\)\
\-\ idiopathic\\:\\ 0\\.016885843304074465\ \(0\)\
\-\ numerous\\:\\ 0\\.01686211787926913\ \(0\)\
\-\ started\\:\\ 0\\.016815144197410727\ \(0\)\
\-\ cbc\\:\\ 0\\.01665553081741586\ \(0\)\
\-\ needed\\:\\ 0\\.016481607485611595\ \(0\)\
\-\ affected\\:\\ 0\\.01641855196426816\ \(0\)\
\-\ abdominal\\:\\ 0\\.01637690462940409\ \(0\)\
\-\ bleeding\\:\\ 0\\.01631592036370231\ \(0\)\
\-\ consistent\\:\\ 0\\.01623606317720894\ \(0\)\
\-\ suggest\\:\\ 0\\.016216213141788872\ \(0\)\
\-\ screening\\:\\ 0\\.016216213141788872\ \(0\)\
\-\ addition\\:\\ 0\\.016157724536498823\ \(0\)\
\-\ follow\\:\\ 0\\.016142156734873903\ \(0\)\
\-\ denies\\:\\ 0\\.016100197431399243\ \(0\)\
\-\ inflammation\\:\\ 0\\.016043600724686042\ \(0\)\
\-\ general\\:\\ 0\\.01602493675108782\ \(0\)\
\-\ previously\\:\\ 0\\.01602493675108782\ \(0\)\
\-\ 35\\:\\ 0\\.016006371791077806\ \(0\)\
\-\ ed\\:\\ 0\\.015969534748256905\ \(0\)\
\-\ immunology\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ histone\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ 552\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ periglomerular\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ arterioles\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ c1q\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ subepithelial\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ endocapillary\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ tubuloredicular\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ fenestrations\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ jets\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ titles\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ nephropthy\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ 650\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ billion\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ dollars\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ medicaid\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ ect\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ mesangium\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ acei\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ arb\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ reassuringly\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ xu\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ kochanek\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ bastian\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ portielje\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ westendorp\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ fakhouri\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ no\\√\\´l\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ glomerulopathy\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ bomback\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ glomerulopathies\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ kuypers\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ evenepoel\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ membranoproliferative\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ dial\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ rabasco\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ cavero\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ rom\\√\\°n\\:\\ 0\\.015962068331831832\ \(0\)\
\-\ neurologic\\:\\ 0\\.015951260624461856\ \(0\)\
\-\ taken\\:\\ 0\\.015951260624461856\ \(0\)\
\-\ noted\\:\\ 0\\.0158760097274296\ \(0\)\
\-\ nodules\\:\\ 0\\.015861294570673208\ \(0\)\
\-\ same\\:\\ 0\\.015790950759888202\ \(0\)\
\-\ upon\\:\\ 0\\.01570496395841917\ \(0\)\
\-\ where\\:\\ 0\\.01568801725820889\ \(0\)\
\-\ initially\\:\\ 0\\.015654368087851252\ \(0\)\
\-\ other\\:\\ 0\\.015550149959107118\ \(0\)\
\-\ reports\\:\\ 0\\.015522916511427409\ \(0\)\
\-\ shown\\:\\ 0\\.015474867883544722\ \(0\)\
\-\ typical\\:\\ 0\\.015427470047179462\ \(0\)\
\-\ sounds\\:\\ 0\\.015411812362201288\ \(0\)\
\-\ glasses\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ pos\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ cores\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ ailments\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ 555\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ photosensitivity\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ seafood\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ spending\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ hosts\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ preventative\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ algorithm\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ immunosuppressives\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ therapeutically\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ informative\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ brand\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ appel\\:\\ 0\\.01525260844420322\ \(0\)\
\-\ rate\\:\\ 0\\.015126900278081147\ \(0\)\
\-\ previous\\:\\ 0\\.015083961251578973\ \(0\)\
\-\ process\\:\\ 0\\.01497196811803344\ \(0\)\
\-\ have\\:\\ 0\\.01495842999948905\ \(0\)\
\-\ 14\\:\\ 0\\.014903749841751334\ \(0\)\
\-\ referred\\:\\ 0\\.014771177672533777\ \(0\)\
\-\ landmarks\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ ssa\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ immunofluorescence\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ ensue\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ figure1\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ statistics\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ singular\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ dipstick\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ immunotherapy\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ jq\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ ba\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ smet\\:\\ 0\\.014749238643169784\ \(0\)\
\-\ course\\:\\ 0\\.01474525542989678\ \(0\)\
\-\ weakness\\:\\ 0\\.014568985024393166\ \(0\)\
\-\ breast\\:\\ 0\\.0144960764132335\ \(0\)\
\-\ female\\:\\ 0\\.0144491288196796\ \(0\)\
\-\ early\\:\\ 0\\.014389484820086632\ \(0\)\
\-\ pmn\\:\\ 0\\.01435879469207598\ \(0\)\
\-\ kappa\\:\\ 0\\.01435879469207598\ \(0\)\
\-\ focusing\\:\\ 0\\.01435879469207598\ \(0\)\
\-\ plausible\\:\\ 0\\.01435879469207598\ \(0\)\
\-\ straightforward\\:\\ 0\\.01435879469207598\ \(0\)\
\-\ surprisingly\\:\\ 0\\.01435879469207598\ \(0\)\
\-\ presence\\:\\ 0\\.014343133324513908\ \(0\)\
\-\ pain\\:\\ 0\\.01428652389713879\ \(0\)\
\-\ middle\\:\\ 0\\.014274737269433492\ \(0\)\
\-\ they\\:\\ 0\\.014263466770949184\ \(0\)\
\-\ muscle\\:\\ 0\\.01417458613933528\ \(0\)\
\-\ 241\\:\\ 0\\.014039778755541172\ \(0\)\
\-\ pearly\\:\\ 0\\.014039778755541172\ \(0\)\
\-\ code\\:\\ 0\\.014039778755541172\ \(0\)\
\-\ cohort\\:\\ 0\\.014039778755541172\ \(0\)\
\-\ amongst\\:\\ 0\\.014039778755541172\ \(0\)\
\-\ rg\\:\\ 0\\.014039778755541172\ \(0\)\
\-\ portosystemic\\:\\ 0\\.014039778755541172\ \(0\)\
\-\ labs\\:\\ 0\\.013830096408408236\ \(0\)\
\-\ within\\:\\ 0\\.013791061325053368\ \(0\)\
\-\ ro\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ fibrinogen\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ normocytic\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ tetanus\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ public\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ understand\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ coat\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ ivp\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ surprising\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ lm\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ lowering\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ kd\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ hc\\:\\ 0\\.01377005462441089\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.01358998258276284\ \(0\)\
\-\ although\\:\\ 0\\.01358998258276284\ \(0\)\
\-\ pigmentation\\:\\ 0\\.013536408954507737\ \(0\)\
\-\ span\\:\\ 0\\.013536408954507737\ \(0\)\
\-\ 152\\:\\ 0\\.013536408954507737\ \(0\)\
\-\ microscopy\\:\\ 0\\.013536408954507737\ \(0\)\
\-\ lh\\:\\ 0\\.013536408954507737\ \(0\)\
\-\ immunohistochemical\\:\\ 0\\.013536408954507737\ \(0\)\
\-\ initial\\:\\ 0\\.013391504889062985\ \(0\)\
\-\ prick\\:\\ 0\\.013330318867912559\ \(0\)\
\-\ pas\\:\\ 0\\.013330318867912559\ \(0\)\
\-\ zero\\:\\ 0\\.013330318867912559\ \(0\)\
\-\ lambda\\:\\ 0\\.013330318867912559\ \(0\)\
\-\ imperative\\:\\ 0\\.013330318867912559\ \(0\)\
\-\ im\\:\\ 0\\.013330318867912559\ \(0\)\
\-\ inactive\\:\\ 0\\.013330318867912559\ \(0\)\
\-\ induction\\:\\ 0\\.013330318867912559\ \(0\)\
\-\ study\\:\\ 0\\.013313446186091465\ \(0\)\
\-\ pmi\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ relapse\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ captions\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ g1p1\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ elbows\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ plays\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ manifested\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ debate\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ sl\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ je\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ house\\:\\ 0\\.013145965003413931\ \(0\)\
\-\ out\\:\\ 0\\.013121531127993299\ \(0\)\
\-\ often\\:\\ 0\\.013025429342780686\ \(0\)\
\-\ injury\\:\\ 0\\.013017538726687804\ \(0\)\
\-\ texture\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ prescription\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ sm\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ capillaries\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ insomnia\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ works\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ ever\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ efforts\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ earliest\\:\\ 0\\.012979196647514363\ \(0\)\
\-\ conjunctiva\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ perirenal\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ jet\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ daughter\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ silent\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ host\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ traditionally\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ reach\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ published\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ int\\:\\ 0\\.012826949066879123\ \(0\)\
\-\ lag\\:\\ 0\\.012686894869228143\ \(0\)\
\-\ anicteric\\:\\ 0\\.012686894869228143\ \(0\)\
\-\ dentition\\:\\ 0\\.012686894869228143\ \(0\)\
\-\ wheeze\\:\\ 0\\.012686894869228143\ \(0\)\
\-\ random\\:\\ 0\\.012686894869228143\ \(0\)\
\-\ context\\:\\ 0\\.012686894869228143\ \(0\)\
\-\ carry\\:\\ 0\\.012686894869228143\ \(0\)\
\-\ gb\\:\\ 0\\.012686894869228143\ \(0\)\
\-\ nares\\:\\ 0\\.01255722493574884\ \(0\)\
\-\ auscultated\\:\\ 0\\.01255722493574884\ \(0\)\
\-\ endothelial\\:\\ 0\\.01255722493574884\ \(0\)\
\-\ hematology\\:\\ 0\\.01255722493574884\ \(0\)\
\-\ begun\\:\\ 0\\.01255722493574884\ \(0\)\
\-\ awareness\\:\\ 0\\.01255722493574884\ \(0\)\
\-\ records\\:\\ 0\\.01255722493574884\ \(0\)\
\-\ carotids\\:\\ 0\\.012436505115785318\ \(0\)\
\-\ interlobular\\:\\ 0\\.012436505115785318\ \(0\)\
\-\ urgency\\:\\ 0\\.012436505115785318\ \(0\)\
\-\ said\\:\\ 0\\.012436505115785318\ \(0\)\
\-\ nephropathy\\:\\ 0\\.012436505115785318\ \(0\)\
\-\ lid\\:\\ 0\\.012323579265845689\ \(0\)\
\-\ babinski\\:\\ 0\\.012323579265845689\ \(0\)\
\-\ eosinophils\\:\\ 0\\.012323579265845689\ \(0\)\
\-\ lft\\:\\ 0\\.012323579265845689\ \(0\)\
\-\ substantial\\:\\ 0\\.012323579265845689\ \(0\)\
\-\ accurately\\:\\ 0\\.012323579265845689\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.012323579265845689\ \(0\)\
\-\ february\\:\\ 0\\.012323579265845689\ \(0\)\
\-\ year\\:\\ 0\\.012304003868011651\ \(0\)\
\-\ primary\\:\\ 0\\.012274689098519552\ \(0\)\
\-\ helped\\:\\ 0\\.012217501735322541\ \(0\)\
\-\ month\\:\\ 0\\.012143325647069068\ \(0\)\
\-\ eventual\\:\\ 0\\.012117489179250509\ \(0\)\
\-\ stabilized\\:\\ 0\\.012117489179250509\ \(0\)\
\-\ why\\:\\ 0\\.012117489179250509\ \(0\)\
\-\ consisted\\:\\ 0\\.012117489179250509\ \(0\)\
\-\ changes\\:\\ 0\\.012064409331850994\ \(0\)\
\-\ syndrome\\:\\ 0\\.01203452454942627\ \(0\)\
\-\ weighing\\:\\ 0\\.012022885416905148\ \(0\)\
\-\ adequately\\:\\ 0\\.012022885416905148\ \(0\)\
\-\ transfusions\\:\\ 0\\.012022885416905148\ \(0\)\
\-\ crampy\\:\\ 0\\.012022885416905148\ \(0\)\
\-\ irregularities\\:\\ 0\\.012022885416905148\ \(0\)\
\-\ retrospective\\:\\ 0\\.012022885416905148\ \(0\)\
\-\ greatly\\:\\ 0\\.012022885416905148\ \(0\)\
\-\ cystic\\:\\ 0\\.012022641730692887\ \(0\)\
\-\ following\\:\\ 0\\.011975509883515959\ \(0\)\
\-\ sclera\\:\\ 0\\.011933135314751882\ \(0\)\
\-\ pin\\:\\ 0\\.011933135314751882\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.011933135314751882\ \(0\)\
\-\ edema\\:\\ 0\\.011905981369522294\ \(0\)\
\-\ all\\:\\ 0\\.011883108825650404\ \(0\)\
\-\ buttocks\\:\\ 0\\.011847765048120226\ \(0\)\
\-\ allowed\\:\\ 0\\.011847765048120226\ \(0\)\
\-\ categories\\:\\ 0\\.011847765048120226\ \(0\)\
\-\ ad\\:\\ 0\\.011847765048120226\ \(0\)\
\-\ secondary\\:\\ 0\\.011832185726946984\ \(0\)\
\-\ quadrants\\:\\ 0\\.011766366958852314\ \(0\)\
\-\ zones\\:\\ 0\\.011766366958852314\ \(0\)\
\-\ igg\\:\\ 0\\.011766366958852314\ \(0\)\
\-\ bruising\\:\\ 0\\.011766366958852314\ \(0\)\
\-\ lives\\:\\ 0\\.011766366958852314\ \(0\)\
\-\ limit\\:\\ 0\\.011766366958852314\ \(0\)\
\-\ shows\\:\\ 0\\.011716170016557352\ \(0\)\
\-\ tm\\:\\ 0\\.011688587781685768\ \(0\)\
\-\ calculi\\:\\ 0\\.011688587781685768\ \(0\)\
\-\ exclusion\\:\\ 0\\.011688587781685768\ \(0\)\
\-\ therapies\\:\\ 0\\.011688587781685768\ \(0\)\
\-\ investigation\\:\\ 0\\.011688587781685768\ \(0\)\
\-\ gender\\:\\ 0\\.011688587781685768\ \(0\)\
\-\ presented\\:\\ 0\\.01164090933624593\ \(0\)\
\-\ bmi\\:\\ 0\\.011614119378217075\ \(0\)\
\-\ ana\\:\\ 0\\.011614119378217075\ \(0\)\
\-\ plasma\\:\\ 0\\.011614119378217075\ \(0\)\
\-\ ha\\:\\ 0\\.011614119378217075\ \(0\)\
\-\ interestingly\\:\\ 0\\.011614119378217075\ \(0\)\
\-\ min\\:\\ 0\\.011542691363658075\ \(0\)\
\-\ ab\\:\\ 0\\.011542691363658075\ \(0\)\
\-\ global\\:\\ 0\\.011542691363658075\ \(0\)\
\-\ lipid\\:\\ 0\\.011542691363658075\ \(0\)\
\-\ significant\\:\\ 0\\.011525818681836981\ \(0\)\
\-\ inspection\\:\\ 0\\.011474065180566094\ \(0\)\
\-\ illicit\\:\\ 0\\.011474065180566094\ \(0\)\
\-\ phases\\:\\ 0\\.011474065180566094\ \(0\)\
\-\ varies\\:\\ 0\\.011474065180566094\ \(0\)\
\-\ cm\\:\\ 0\\.011464601609054114\ \(0\)\
\-\ responsible\\:\\ 0\\.011408029291621897\ \(0\)\
\-\ perrla\\:\\ 0\\.01134439524708679\ \(0\)\
\-\ consist\\:\\ 0\\.01134439524708679\ \(0\)\
\-\ decision\\:\\ 0\\.01134439524708679\ \(0\)\
\-\ evidence\\:\\ 0\\.011330657346368223\ \(0\)\
\-\ mild\\:\\ 0\\.011316086249308731\ \(0\)\
\-\ than\\:\\ 0\\.011316086249308731\ \(0\)\
\-\ bpm\\:\\ 0\\.01128299444264716\ \(0\)\
\-\ respirations\\:\\ 0\\.01128299444264716\ \(0\)\
\-\ atraumatic\\:\\ 0\\.01128299444264716\ \(0\)\
\-\ albumin\\:\\ 0\\.01128299444264716\ \(0\)\
\-\ fibroids\\:\\ 0\\.01128299444264716\ \(0\)\
\-\ decades\\:\\ 0\\.01128299444264716\ \(0\)\
\-\ microscopic\\:\\ 0\\.011223675427123268\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.011223675427123268\ \(0\)\
\-\ 2015\\:\\ 0\\.011223675427123268\ \(0\)\
\-\ prior\\:\\ 0\\.011168967515018289\ \(0\)\
\-\ ears\\:\\ 0\\.011166301651796698\ \(0\)\
\-\ dm\\:\\ 0\\.011166301651796698\ \(0\)\
\-\ office\\:\\ 0\\.011166301651796698\ \(0\)\
\-\ histologic\\:\\ 0\\.011166301651796698\ \(0\)\
\-\ grey\\:\\ 0\\.011110749577183639\ \(0\)\
\-\ cmp\\:\\ 0\\.011110749577183639\ \(0\)\
\-\ indication\\:\\ 0\\.011110749577183639\ \(0\)\
\-\ accounts\\:\\ 0\\.011110749577183639\ \(0\)\
\-\ moist\\:\\ 0\\.0110569070712237\ \(0\)\
\-\ regimen\\:\\ 0\\.0110569070712237\ \(0\)\
\-\ heat\\:\\ 0\\.0110569070712237\ \(0\)\
\-\ intolerance\\:\\ 0\\.011004672046660492\ \(0\)\
\-\ likelihood\\:\\ 0\\.011004672046660492\ \(0\)\
\-\ begins\\:\\ 0\\.010953951295992985\ \(0\)\
\-\ symptoms\\:\\ 0\\.010922264789671598\ \(0\)\
\-\ august\\:\\ 0\\.010904659490588463\ \(0\)\
\-\ photophobia\\:\\ 0\\.010904659490588463\ \(0\)\
\-\ murphy\\:\\ 0\\.010904659490588463\ \(0\)\
\-\ post\\:\\ 0\\.010862149428501847\ \(0\)\
\-\ normocephalic\\:\\ 0\\.010856718316958662\ \(0\)\
\-\ eomi\\:\\ 0\\.010856718316958662\ \(0\)\
\-\ constipation\\:\\ 0\\.010856718316958662\ \(0\)\
\-\ them\\:\\ 0\\.010856718316958662\ \(0\)\
\-\ aids\\:\\ 0\\.010856718316958662\ \(0\)\
\-\ mmhg\\:\\ 0\\.010810055728243098\ \(0\)\
\-\ acute\\:\\ 0\\.010798865845849425\ \(0\)\
\-\ finally\\:\\ 0\\.01076460529293748\ \(0\)\
\-\ surgery\\:\\ 0\\.010732601394889102\ \(0\)\
\-\ plt\\:\\ 0\\.010720305626089832\ \(0\)\
\-\ proliferation\\:\\ 0\\.010720305626089832\ \(0\)\
\-\ severely\\:\\ 0\\.010720305626089832\ \(0\)\
\-\ documented\\:\\ 0\\.010677099890742198\ \(0\)\
\-\ identify\\:\\ 0\\.010634935359458178\ \(0\)\
\-\ 2010\\:\\ 0\\.010634935359458178\ \(0\)\
\-\ rhonchi\\:\\ 0\\.010593763027450688\ \(0\)\
\-\ already\\:\\ 0\\.010593763027450688\ \(0\)\
\-\ prominence\\:\\ 0\\.010553537270190264\ \(0\)\
\-\ heard\\:\\ 0\\.010553537270190264\ \(0\)\
\-\ hemoglobin\\:\\ 0\\.010553537270190264\ \(0\)\
\-\ interesting\\:\\ 0\\.010553537270190264\ \(0\)\
\-\ ulcers\\:\\ 0\\.010514215539494654\ \(0\)\
\-\ prescribed\\:\\ 0\\.010514215539494654\ \(0\)\
\-\ never\\:\\ 0\\.010514215539494654\ \(0\)\
\-\ membranes\\:\\ 0\\.010475758093023719\ \(0\)\
\-\ appetite\\:\\ 0\\.010475758093023719\ \(0\)\
\-\ role\\:\\ 0\\.010475758093023719\ \(0\)\
\-\ allergies\\:\\ 0\\.010438127752868006\ \(0\)\
\-\ individuals\\:\\ 0\\.010438127752868006\ \(0\)\
\-\ ureteral\\:\\ 0\\.010401289689555025\ \(0\)\
\-\ knees\\:\\ 0\\.010401289689555025\ \(0\)\
\-\ gallops\\:\\ 0\\.010365211228327894\ \(0\)\
\-\ effects\\:\\ 0\\.010365211228327894\ \(0\)\
\-\ social\\:\\ 0\\.010365211228327894\ \(0\)\
\-\ sob\\:\\ 0\\.010329861674996027\ \(0\)\
\-\ affect\\:\\ 0\\.010329861674996027\ \(0\)\
\-\ lbs\\:\\ 0\\.010295212159031878\ \(0\)\
\-\ visit\\:\\ 0\\.010295212159031878\ \(0\)\
\-\ scarring\\:\\ 0\\.010295212159031878\ \(0\)\
\-\ question\\:\\ 0\\.010295212159031878\ \(0\)\
\-\ organ\\:\\ 0\\.010261235491904044\ \(0\)\
\-\ smoker\\:\\ 0\\.010227906038905017\ \(0\)\
\-\ lower\\:\\ 0\\.010200780485435781\ \(0\)\
\-\ monitor\\:\\ 0\\.010195199602959849\ \(0\)\
\-\ sweats\\:\\ 0\\.010195199602959849\ \(0\)\
\-\ effective\\:\\ 0\\.010195199602959849\ \(0\)\
\-\ 78\\:\\ 0\\.010163093319096459\ \(0\)\
\-\ produced\\:\\ 0\\.010163093319096459\ \(0\)\
\-\ deformities\\:\\ 0\\.010131565558424743\ \(0\)\
\-\ nose\\:\\ 0\\.010100595840614486\ \(0\)\
\-\ treat\\:\\ 0\\.010100595840614486\ \(0\)\
\-\ against\\:\\ 0\\.010100595840614486\ \(0\)\
\-\ therapeutic\\:\\ 0\\.010100595840614486\ \(0\)\
\-\ stability\\:\\ 0\\.01007016475398511\ \(0\)\
\-\ throat\\:\\ 0\\.010010845738461218\ \(0\)\
\-\ core\\:\\ 0\\.010010845738461218\ \(0\)\
\-\ future\\:\\ 0\\.010010845738461218\ \(0\)\
\-\ drugs\\:\\ 0\\.0099819237018411\ \(0\)\
\-\ making\\:\\ 0\\.0099819237018411\ \(0\)\
\-\ transplant\\:\\ 0\\.0099819237018411\ \(0\)\
\-\ htn\\:\\ 0\\.00995347196313465\ \(0\)\
\-\ nih\\:\\ 0\\.00995347196313465\ \(0\)\
\-\ tone\\:\\ 0\\.00989791988852159\ \(0\)\
\-\ discussed\\:\\ 0\\.00989791988852159\ \(0\)\
\-\ combined\\:\\ 0\\.00989791988852159\ \(0\)\
\-\ reflex\\:\\ 0\\.009870791540810239\ \(0\)\
\-\ smith\\:\\ 0\\.009870791540810239\ \(0\)\
\-\ health\\:\\ 0\\.009870791540810239\ \(0\)\
\-\ stated\\:\\ 0\\.009870791540810239\ \(0\)\
\-\ fields\\:\\ 0\\.009817764956234763\ \(0\)\
\-\ rales\\:\\ 0\\.009817764956234763\ \(0\)\
\-\ legs\\:\\ 0\\.009817764956234763\ \(0\)\
\-\ touch\\:\\ 0\\.009791842357998444\ \(0\)\
\-\ aneurysmal\\:\\ 0\\.009791842357998444\ \(0\)\
\-\ procedures\\:\\ 0\\.009791842357998444\ \(0\)\
\-\ capsule\\:\\ 0\\.009766298205395105\ \(0\)\
\-\ collections\\:\\ 0\\.009766298205395105\ \(0\)\
\-\ managed\\:\\ 0\\.009766298205395105\ \(0\)\
\-\ multiple\\:\\ 0\\.009764017765317696\ \(0\)\
\-\ cn\\:\\ 0\\.009741121607330936\ \(0\)\
\-\ dizziness\\:\\ 0\\.009741121607330936\ \(0\)\
\-\ impression\\:\\ 0\\.009716302136194689\ \(0\)\
\-\ spleen\\:\\ 0\\.009716302136194689\ \(0\)\
\-\ eyes\\:\\ 0\\.009691829801926413\ \(0\)\
\-\ support\\:\\ 0\\.009691829801926413\ \(0\)\
\-\ after\\:\\ 0\\.00968406116270623\ \(0\)\
\-\ trachea\\:\\ 0\\.009667695027874727\ \(0\)\
\-\ fatigue\\:\\ 0\\.009667695027874727\ \(0\)\
\-\ prostate\\:\\ 0\\.009667695027874727\ \(0\)\
\-\ wide\\:\\ 0\\.009667695027874727\ \(0\)\
\-\ well\\:\\ 0\\.009665866216581493\ \(0\)\
\-\ mucosa\\:\\ 0\\.009620401787367413\ \(0\)\
\-\ percutaneous\\:\\ 0\\.009620401787367413\ \(0\)\
\-\ s2\\:\\ 0\\.00959722603958105\ \(0\)\
\-\ we\\:\\ 0\\.00959722603958105\ \(0\)\
\-\ murmurs\\:\\ 0\\.009574353251431368\ \(0\)\
\-\ fact\\:\\ 0\\.009574353251431368\ \(0\)\
\-\ reduced\\:\\ 0\\.009574353251431368\ \(0\)\
\-\ equal\\:\\ 0\\.009551775604275432\ \(0\)\
\-\ continues\\:\\ 0\\.009529485578288432\ \(0\)\
\-\ 62\\:\\ 0\\.009507475937427784\ \(0\)\
\-\ experienced\\:\\ 0\\.009485739715331235\ \(0\)\
\-\ frequency\\:\\ 0\\.009485739715331235\ \(0\)\
\-\ rhythm\\:\\ 0\\.009464270202080148\ \(0\)\
\-\ pulses\\:\\ 0\\.009464270202080148\ \(0\)\
\-\ musculoskeletal\\:\\ 0\\.009464270202080148\ \(0\)\
\-\ each\\:\\ 0\\.009464270202080148\ \(0\)\
\-\ shunt\\:\\ 0\\.009464270202080148\ \(0\)\
\-\ atrophy\\:\\ 0\\.009443060931765107\ \(0\)\
\-\ nuclear\\:\\ 0\\.009443060931765107\ \(0\)\
\-\ diarrhea\\:\\ 0\\.009443060931765107\ \(0\)\
\-\ population\\:\\ 0\\.009443060931765107\ \(0\)\
\-\ late\\:\\ 0\\.009422105670796129\ \(0\)\
\-\ sinuses\\:\\ 0\\.009401398406904637\ \(0\)\
\-\ mucosal\\:\\ 0\\.009401398406904637\ \(0\)\
\-\ workup\\:\\ 0\\.009401398406904637\ \(0\)\
\-\ advanced\\:\\ 0\\.00938093333878864\ \(0\)\
\-\ possibly\\:\\ 0\\.00938093333878864\ \(0\)\
\-\ wnl\\:\\ 0\\.009360704866356498\ \(0\)\
\-\ uterine\\:\\ 0\\.009320936259556486\ \(0\)\
\-\ adults\\:\\ 0\\.009320936259556486\ \(0\)\
\-\ analysis\\:\\ 0\\.009282051473145148\ \(0\)\
\-\ possibility\\:\\ 0\\.009282051473145148\ \(0\)\
\-\ needle\\:\\ 0\\.009262928404361671\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.009262928404361671\ \(0\)\
\-\ combination\\:\\ 0\\.009262928404361671\ \(0\)\
\-\ alcohol\\:\\ 0\\.009225298064205958\ \(0\)\
\-\ develop\\:\\ 0\\.009188460000892977\ \(0\)\
\-\ rr\\:\\ 0\\.009170327782907411\ \(0\)\
\-\ help\\:\\ 0\\.009170327782907411\ \(0\)\
\-\ anemia\\:\\ 0\\.009170327782907411\ \(0\)\
\-\ diseases\\:\\ 0\\.009170327782907411\ \(0\)\
\-\ prevent\\:\\ 0\\.009152381539665846\ \(0\)\
\-\ concern\\:\\ 0\\.009152381539665846\ \(0\)\
\-\ earlier\\:\\ 0\\.009117031986333977\ \(0\)\
\-\ chills\\:\\ 0\\.00908238247036983\ \(0\)\
\-\ patent\\:\\ 0\\.009048405803241996\ \(0\)\
\-\ pmh\\:\\ 0\\.009031661719702322\ \(0\)\
\-\ lab\\:\\ 0\\.009015076350242969\ \(0\)\
\-\ color\\:\\ 0\\.008998646714251499\ \(0\)\
\-\ times\\:\\ 0\\.0089823699142978\ \(0\)\
\-\ six\\:\\ 0\\.008966243133067325\ \(0\)\
\-\ night\\:\\ 0\\.008966243133067325\ \(0\)\
\-\ completely\\:\\ 0\\.008918735869762693\ \(0\)\
\-\ 42\\:\\ 0\\.008872484453267864\ \(0\)\
\-\ gross\\:\\ 0\\.008857335065323062\ \(0\)\
\-\ still\\:\\ 0\\.008842315716646818\ \(0\)\
\-\ painful\\:\\ 0\\.008827424193764347\ \(0\)\
\-\ home\\:\\ 0\\.008827424193764347\ \(0\)\
\-\ disorders\\:\\ 0\\.008812658339239547\ \(0\)\
\-\ visible\\:\\ 0\\.00879801604979917\ \(0\)\
\-\ states\\:\\ 0\\.008769094013179051\ \(0\)\
\-\ discussion\\:\\ 0\\.0087406422744726\ \(0\)\
\-\ reflexes\\:\\ 0\\.008726588035240172\ \(0\)\
\-\ major\\:\\ 0\\.008726588035240172\ \(0\)\
\-\ form\\:\\ 0\\.008726588035240172\ \(0\)\
\-\ s1\\:\\ 0\\.008712645783167517\ \(0\)\
\-\ gait\\:\\ 0\\.008644553791310725\ \(0\)\
\-\ 48\\:\\ 0\\.008644553791310725\ \(0\)\
\-\ much\\:\\ 0\\.008644553791310725\ \(0\)\
\-\ kidneys\\:\\ 0\\.008591925963203993\ \(0\)\
\-\ hr\\:\\ 0\\.008579012669336394\ \(0\)\
\-\ node\\:\\ 0\\.008579012669336394\ \(0\)\
\-\ deficits\\:\\ 0\\.008579012669336394\ \(0\)\
\-\ sensation\\:\\ 0\\.008553468516733057\ \(0\)\
\-\ those\\:\\ 0\\.00854083493565916\ \(0\)\
\-\ visual\\:\\ 0\\.008515838176577346\ \(0\)\
\-\ focus\\:\\ 0\\.00845486533921268\ \(0\)\
\-\ factors\\:\\ 0\\.008442921652037232\ \(0\)\
\-\ report\\:\\ 0\\.008407572098705364\ \(0\)\
\-\ even\\:\\ 0\\.00839594585408835\ \(0\)\
\-\ strength\\:\\ 0\\.00836152356276932\ \(0\)\
\-\ fibrosis\\:\\ 0\\.00836152356276932\ \(0\)\
\-\ supportive\\:\\ 0\\.008338945915613384\ \(0\)\
\-\ until\\:\\ 0\\.008305616462614355\ \(0\)\
\-\ their\\:\\ 0\\.008283744385602773\ \(0\)\
\-\ do\\:\\ 0\\.008272910026669186\ \(0\)\
\-\ either\\:\\ 0\\.0082514405134181\ \(0\)\
\-\ recurrence\\:\\ 0\\.008240803742805797\ \(0\)\
\-\ review\\:\\ 0\\.008219722242279945\ \(0\)\
\-\ using\\:\\ 0\\.00820927598213408\ \(0\)\
\-\ total\\:\\ 0\\.008178306264323825\ \(0\)\
\-\ another\\:\\ 0\\.008168103650126591\ \(0\)\
\-\ foci\\:\\ 0\\.008157960181851154\ \(0\)\
\-\ dilatation\\:\\ 0\\.008147875177694448\ \(0\)\
\-\ bp\\:\\ 0\\.008098304061350346\ \(0\)\
\-\ four\\:\\ 0\\.008088556162170557\ \(0\)\
\-\ external\\:\\ 0\\.0080692217844831\ \(0\)\
\-\ mildly\\:\\ 0\\.008059634125550438\ \(0\)\
\-\ distress\\:\\ 0\\.008040614988540758\ \(0\)\
\-\ etiology\\:\\ 0\\.008040614988540758\ \(0\)\
\-\ oral\\:\\ 0\\.007993952399825196\ \(0\)\
\-\ just\\:\\ 0\\.007984767374128452\ \(0\)\
\-\ around\\:\\ 0\\.007966540715804054\ \(0\)\
\-\ references\\:\\ 0\\.007957498094245364\ \(0\)\
\-\ administration\\:\\ 0\\.007948501964519575\ \(0\)\
\-\ recommended\\:\\ 0\\.007939551851003796\ \(0\)\
\-\ from\\:\\ 0\\.007928197414879969\ \(0\)\
\-\ arteries\\:\\ 0\\.00792178780627099\ \(0\)\
\-\ rule\\:\\ 0\\.00792178780627099\ \(0\)\
\-\ levels\\:\\ 0\\.007912972959530992\ \(0\)\
\-\ especially\\:\\ 0\\.007895475379944101\ \(0\)\
\-\ stable\\:\\ 0\\.007895475379944101\ \(0\)\
\-\ foot\\:\\ 0\\.007886791772159897\ \(0\)\
\-\ many\\:\\ 0\\.00786955278170778\ \(0\)\
\-\ appear\\:\\ 0\\.007860996562324293\ \(0\)\
\-\ family\\:\\ 0\\.007852481979209585\ \(0\)\
\-\ thyroid\\:\\ 0\\.007844008629104445\ \(0\)\
\-\ pathology\\:\\ 0\\.007835576114579947\ \(0\)\
\-\ results\\:\\ 0\\.007777659699032785\ \(0\)\
\-\ lymph\\:\\ 0\\.007761458255713704\ \(0\)\
\-\ fibrous\\:\\ 0\\.007753413444405275\ \(0\)\
\-\ circumscribed\\:\\ 0\\.0077294985840568\ \(0\)\
\-\ made\\:\\ 0\\.0076981122110767524\ \(0\)\
\-\ symptomatic\\:\\ 0\\.007674936463290389\ \(0\)\
\-\ nausea\\:\\ 0\\.007667278930817914\ \(0\)\
\-\ currently\\:\\ 0\\.007667278930817914\ \(0\)\
\-\ use\\:\\ 0\\.007636979587092435\ \(0\)\
\-\ hypertension\\:\\ 0\\.007636979587092435\ \(0\)\
\-\ removal\\:\\ 0\\.00762948602798477\ \(0\)\
\-\ vs\\:\\ 0\\.007614594505102298\ \(0\)\
\-\ diagnostic\\:\\ 0\\.007607196001997768\ \(0\)\
\-\ similar\\:\\ 0\\.007607196001997768\ \(0\)\
\-\ ct\\:\\ 0\\.007599852448159378\ \(0\)\
\-\ extremities\\:\\ 0\\.007585186361137123\ \(0\)\
\-\ specific\\:\\ 0\\.0075634501390405735\ \(0\)\
\-\ note\\:\\ 0\\.007513758346578123\ \(0\)\
\-\ 60\\:\\ 0\\.007465438890949818\ \(0\)\
\-\ skin\\:\\ 0\\.007425058405531069\ \(0\)\
\-\ developed\\:\\ 0\\.0074052123321601045\ \(0\)\
\-\ hospital\\:\\ 0\\.00737262771494839\ \(0\)\
\-\ management\\:\\ 0\\.00737262771494839\ \(0\)\
\-\ lungs\\:\\ 0\\.007366182980674345\ \(0\)\
\-\ breath\\:\\ 0\\.007315462230006838\ \(0\)\
\-\ appears\\:\\ 0\\.007309224279095962\ \(0\)\
\-\ ago\\:\\ 0\\.007303008487915296\ \(0\)\
\-\ could\\:\\ 0\\.007260105450151197\ \(0\)\
\-\ clear\\:\\ 0\\.007236053616083758\ \(0\)\
\-\ intact\\:\\ 0\\.007224150554008492\ \(0\)\
\-\ reported\\:\\ 0\\.0071889196313676944\ \(0\)\
\-\ peripheral\\:\\ 0\\.007137368634716746\ \(0\)\
\-\ otherwise\\:\\ 0\\.007114935720045881\ \(0\)\
\-\ identified\\:\\ 0\\.007076357137960837\ \(0\)\
\-\ then\\:\\ 0\\.0070654891317338065\ \(0\)\
\-\ would\\:\\ 0\\.0070654891317338065\ \(0\)\
\-\ involving\\:\\ 0\\.006991246457914819\ \(0\)\
\-\ weight\\:\\ 0\\.0069603678322449\ \(0\)\
\-\ being\\:\\ 0\\.006955273961464543\ \(0\)\
\-\ heart\\:\\ 0\\.006940080725247558\ \(0\)\
\-\ does\\:\\ 0\\.006900198807776785\ \(0\)\
\-\ liver\\:\\ 0\\.006885474372688298\ \(0\)\
\-\ underwent\\:\\ 0\\.00687572647350851\ \(0\)\
\-\ now\\:\\ 0\\.006851591699456825\ \(0\)\
\-\ masses\\:\\ 0\\.00679499129138142\ \(0\)\
\-\ fever\\:\\ 0\\.006767363190371246\ \(0\)\
\-\ size\\:\\ 0\\.006758249923013464\ \(0\)\
\-\ inflammatory\\:\\ 0\\.006749183874869365\ \(0\)\
\-\ followed\\:\\ 0\\.006740164559139679\ \(0\)\
\-\ first\\:\\ 0\\.0067356722758575285\ \(0\)\
\-\ type\\:\\ 0\\.0066957524445314925\ \(0\)\
\-\ back\\:\\ 0\\.006656723093045732\ \(0\)\
\-\ cancer\\:\\ 0\\.006648166873662245\ \(0\)\
\-\ vascular\\:\\ 0\\.006589416972918871\ \(0\)\
\-\ white\\:\\ 0\\.006585295078486733\ \(0\)\
\-\ should\\:\\ 0\\.006512714671390343\ \(0\)\
\-\ differential\\:\\ 0\\.006485282522414703\ \(0\)\
\-\ adjacent\\:\\ 0\\.006469797966692365\ \(0\)\
\-\ while\\:\\ 0\\.006450633006450554\ \(0\)\
\-\ onset\\:\\ 0\\.0064091947357880555\ \(0\)\
\-\ bowel\\:\\ 0\\.006405475832417268\ \(0\)\
\-\ examination\\:\\ 0\\.006386998961915449\ \(0\)\
\-\ approximately\\:\\ 0\\.006368715165692922\ \(0\)\
\-\ day\\:\\ 0\\.006357835897210744\ \(0\)\
\-\ some\\:\\ 0\\.006280056720044199\ \(0\)\
\-\ tenderness\\:\\ 0\\.006259430822535444\ \(0\)\
\-\ diffuse\\:\\ 0\\.006259430822535444\ \(0\)\
\-\ see\\:\\ 0\\.006208905366625356\ \(0\)\
\-\ decreased\\:\\ 0\\.006182543385833596\ \(0\)\
\-\ ultrasound\\:\\ 0\\.006156572691958751\ \(0\)\
\-\ demonstrated\\:\\ 0\\.006134160302016506\ \(0\)\
\-\ neck\\:\\ 0\\.006105759876184949\ \(0\)\
\-\ abdomen\\:\\ 0\\.006090178799253248\ \(0\)\
\-\ wall\\:\\ 0\\.006071662823534534\ \(0\)\
\-\ when\\:\\ 0\\.006029205961888583\ \(0\)\
\-\ carcinoma\\:\\ 0\\.005970286476764252\ \(0\)\
\-\ head\\:\\ 0\\.005952990684761147\ \(0\)\
\-\ through\\:\\ 0\\.005941554412825202\ \(0\)\
\-\ two\\:\\ 0\\.005927363391183368\ \(0\)\
\-\ trauma\\:\\ 0\\.005796684203839045\ \(0\)\
\-\ fluid\\:\\ 0\\.005762909340918491\ \(0\)\
\-\ who\\:\\ 0\\.005645967553073476\ \(0\)\
\-\ over\\:\\ 0\\.005549970934906831\ \(0\)\
\-\ more\\:\\ 0\\.005480731467696665\ \(0\)\
\-\ physical\\:\\ 0\\.005412021059069647\ \(0\)\
\-\ upper\\:\\ 0\\.00533378420530891\ \(0\)\
\-\ into\\:\\ 0\\.005305819674830131\ \(0\)\
\-\ chest\\:\\ 0\\.005268568829100628\ \(0\)\
\-\ can\\:\\ 0\\.005237803317788506\ \(0\)\
\-\ most\\:\\ 0\\.005194504607421465\ \(0\)\
\-\ small\\:\\ 0\\.005148625120650062\ \(0\)\
\-\ present\\:\\ 0\\.005121663980486001\ \(0\)\
\-\ exam\\:\\ 0\\.005024527416669758\ \(0\)\
\-\ large\\:\\ 0\\.005001063073389238\ \(0\)\
\-\ surgical\\:\\ 0\\.004851175602400009\ \(0\)\
\-\ seen\\:\\ 0\\.004699055373078723\ \(0\)\
\-\ images\\:\\ 0\\.004616956966260026\ \(0\)\
\-\ an\\:\\ 0\\.0038167670025643897\ \(0\)\
\-\ mass\\:\\ 0\\.0038125415878635994\ \(0\)\
